Note: Descriptions are shown in the official language in which they were submitted.
73 ~ (~
ASCOR~ATE INTERFERENCE-RESISTANT COMPOSITION, DEVICE
AND MET~OD OF ASSAYING FOR A PREDETERMINED ANALYTE
FIELD OF T~E INYEN~ION
The present invention relates to a
compo~ition, device and method of determining the
presence or concentration of a predetermined analyte in
a te~t ~ample. More particularly, the present invention
relates to a new and improved method of assaying a
liquid te~t sample, like a biological ~ample, such as
urine, blood pla~ma or blood serum, for a predetermined
analyte, like an analyte capable of in~eracting with an
oxidase en~yme, such as glucose or cholesterol, or like
a peroxidatively active substance/ such as occult blood,
by utilizing an indica~or reagent composition that
effectively re~i~ts ascorbate interference. The
indicator reagent composition undergoes a detectable or
a mea~urable response upon contact with a test sample
containing the predetermined analyte. The indicator
reagent compo~ition of the present invention provide~ a
more accurate and ~ensitive as3ay for the predetermined
analyte by essentially elimina~ing the interfering
affect~ of ascorbate presen~ in the te~t sample.
Accordingly, the improved sensitivity achieved by the
indicator reagent composition of the present inventi.on
provides an improved method of a~saying a test sample
for a low concentration of a pr2determined analyte, such
as as~aying urine for occult blood or glucose, or
a~aying blood serum or blood plasma for glucos
BACKGROUND OF T~E INVENTION AND PRIOR ART
A~ used herel and hereinafter, the expression
"predetermined analyte" is defined as a compound either
~a) that is capable of interacting with an oxidase
enzyme to generate hydrogen peroxide or (b) that
exhibit~ peroxidative activity. Similarly, as used
here, and hereinafter, the ~xpre~ion "redox mediator"
MS-1654
2~6~
-- 2
is defined as a compound, or compounds, capable of
interacting with a pred~termined analyte to generate
molecular oxyyen. The molecular oxygen, in turn,
oxidizes an oxidizable dye to pro~ide a detectable color
change. The "redox mediator" can be a combination of an
oxidase enzyme and peroxidase enzyme, or can be a
hydroperoxide, depending upon the particular
predetermined analyte of interest. Therefore, assays
for a predetermined analyte, like an analyte capable of
interacting with a suitable oxidase enzyme and
peroxidase, such as glucose, or like a peroxidatively
active substance, such as occult blood, i~e.,
hemoglobin, are ba~ed upon a chromogenic interaction,
wherein the degree and intensity of a color transition
of an oxidizable indicator dye are correlated to the
concentration of the predetermined analyte in a te~t
sample~ ~ssays for a predetermin~d analyte are
particularly useful in detecting and measuring low
concentratlons of analyte in body fluid sample such as
blood, urine, feces or gastrointestinal contents~
For example, glucose is the sugar most
commonly found in urine. The presenoe of detectable
amounts of glucose in urine is known as glycosuria.
Glycosuria can be a benign or a pathological condition,
and the phy~ician must distingui~h between the two
t~p~s.
Glycosuria can occur when blood glucose levels
are normal because reab~orption of glucose in the
kidney~ is below normal, thus permitting some glucose to
spill into the urine. This is a benign condition, as is
the occurrence of glycosuria after eating a heavy meal
or in conjunction with emotional stre~s. However,
diabetes mellitus is a pathological state and i~ the
chief causa of glycosuria. Indications of diabetes
melli~us include a marked elevation of blood glucose and
an increase in urine volume. The urine gluco3e content
MS-1654
~67~
-- 3 --
of a diabetic individual can be as high as 10%, with a
content of 2~ to 5% commonly being found.
Various assays are available to test urine for
glucose. The mo~t commonly used assay is an enzymatic
test based on an interaction between glucose oxidase and
glucose. The en2ymatic glucose oxidase test for
glucose, as applied to urine, is specific for glu~ose.
Other sugars, such as lactose/ fructose, galactose and
pentose, are not substr~tes for the glucose oxidase
enzyme, and, therefore, are not detected or measured.
In a standard assay o~ a test sample for
glucose, glucose oxidase, in the presence of oxygen,
first converts the glucose in the t~st sample to
gluconic acid and hydrogen peroxide. Then, the
peroxidase enzyme, also presen~ in ~he assay, catalyzes
an interaction between the hydrogen peroxide and an
oxidizable dye compound, like o-tolidine. The dye
compound, usually essentially colorles~ in its reduced
state, undergoes a color transition upon oxidation, such
as to a blue color ~or o-tolidine, by the peroxida~e-
catalyzed interaction with hydrogen peroxide. The
degree and intensity of the color transition are
directly proportional to the amount of hydrogen peroxide
generated by the glucose conversion. Then, the amount
of hydrogen peroxide generated by the glucose conversion
i9 correlated to the original concentration of glucose
in the urin~ sample. In practice, a ~e3t strip is
dipped into the urine sample, and the resul~ing color
transition of the test strip is compared to a color
chart ranging from colorless, indicating less than 0.1%
concentration of glucose, to blue, indicating a 2.0% or
greater concentration in the urine.
Peroxidase is an enzyme that catalyze~ the
oxidation of variouQ compound~, such as phenol~ and
amines, by peroxid0s. In addition, particular compound~
have been termed pseudoperoxidases because these
MS-1654
2~678~
compounds behave in a manner similar to the peroxidase
enzyme. Accordingly, pseudoperoxidases liberate oxygen
from hydroperoxides, and transfer the oxygen to certain
acceptor compounds. Therefore, in general, the
pseudoperoxidases are enzyme-like in that they catalyze,
or otherwise participate in, interactions between
peroxides and oxidizable compound~, like oxidizable dye
compounds. The pseudoperoxidases also are termed
peroxidatively active substances, and include hemoglobin
and its deriva~ives.
Therefore, a peroxidatively active substance,
like hemoglobin, a hemoglobin derivative, an
erythrocyte, myoglobin or a combination thereof,
catalyzes an interaction between a hydroperoxide and an
oxidizable dye. In such interactions, the
peroxidatively active substance imitates the peroxidase
enzyme, and catalyzes or otherwise participates in an
interaction between the oxidizable dye and the
hydroperoxide. The oxygen liberated from a
hydroperoxide by a peroxidatively active substance is
transferred to an oxidi able dye. The resulting
interaction provides a detect ble response, such as a
color transition, wherein the intensity and degree of
the response are indicative of the presence or the
concentration of the peroxidatively active substance.
For example, a low concentration of blood in
the urine i~ termed "occult blood." Occult blood is
detected by assaying for the peroxidatively active
compound hemoglobin. Although oceult blood in urine,
feces or vomit usually is not visible to the naked eye,
the detection of occult blood is impor~ant in the
diagnosis of hemorrhages in the stomach, intestines and
urinary tract. The hemorrhages are caused, for example,
by tumors, ulcers or inflammations of the organ in
question. Presently, most methods of determining the
presence of occult blood in a test sample are based upon
MS-1654
8 6 ~
-- 5 --
the pseudoperoxid~se activity of hemoglobin or
myoglobin.
The presence of blood in urine also is an
indication of damage to the kidney or urinary tract.
Normally, detectable amounts of occult blood are not
present in urine, even with very sensitive chemical
methods. The presence of blood in urine or feces i9 a
symptom of a variety of abnormal conditions, including
cancer. The presence of blood in urine, as indicated by
a positi~e test for occult blood, often indicates
bleeding in the urinary tract. Free hemoglobin is
present in the urine because of renal disorders,
infectious diseases, neoplasmsr or traumas affeeting
part of the urinary tract. Free hemoglobin in the urine
also can indicate a transfusion reaction, hemolytic
anemia, or paroxysmal hemoglobinuria, or can appear from
various poisonings or following severe burns.
Therefore, accurate and sensitive assays of
blood, urine and other test samples for various
predetermined analytes must be available for both
laboratory and home use. The assays should provide an
accurate detection and measurement of the predetermined
analyte such that a correct diagnosis can be made and
corre t medical treatment implemented, monitored and
maintained. In addition, it would ke advantageous if
the a~say method could be utilized in a dip-and-read
form~t for ~he easy and economical, qualitative or
quantitative determination of a predetermined analyte in
blood, urine or other test sample~.
Furthermore, any method of assaying for a
particular predetermined analyte in blood, urine or
other te3t samples must yield accurate, trustworthy and
reproducible results by utili~ing an indicator reagent
composition that undergoes a color transition as a
result of an interaction with the predetermined analyte,
and not as a result of a competing chemical or physical
MS-1654
~7~
-- 6 --
interaction, such as a preferential interaction with a
test sample component, like ascorbate, other than the
predetermined analyteO Moreover, it would be
advantageous if the assay method for the predetermined
analyte is suitable for use in dry phase rea~ent strips
for t~e rapid, economical and accurate determination of
the predetermined analyte in blood, urine or other test
samples. Additionally, the method and composition
utilized in the assay for the predetermined analyte
should not adversely affect or interfere with the other
te t reagent pads that are present on multideterminant
reagent s~rips.
In order to determine if a body fluid of an
individual includes a clinically-significant amount of a
predetermined analyte, and in order to monitor the
course of medical treatment to determine the
effectiveness of the treatment, ~imple, accurate and
inexpensive detection assays for predetermined analytes,
like glucose and occult blood, have been developed.
Furthermore, of the ~everal different assay methods
developed for the detection or measurement of a
predetermined analyte in a test sample, the methods
ba~ed on dip-and-read dry phase test strips have proven
especially useful because dry phase test strip me~hods
are readily automated and provide reproducible and
accurate re~ults.
Some test strips used in assays for a
predetermined analyte have a single test area consisting
of a small square pad of a suitable carrier matrix
impregnated with an indicator reagent composition
capable of interacting with the predetermined analyte
and undergoing a detectable or measurable change, such
as a color transition. Other test strips are
multideterminant reagent strips that include one test
area for the assay of a particular predetermined analyte
as described above, and further include several
MS-1654
2~866
-- 7 --
additional test areas on the same strip to permit the
simultaneous assay of other clinically-important
constituents present in the test sample. For both types
of colorimetric test strips, the assay for a
predetermined analyte in the test sample, such as blood
or urine, is performed simply by dipping the
colorimetric test strip into the test sample~ then
comparing the resulting color of the test area of the
test strip to a standardized color chart provided on the
colorimetric test strip bottle. For example, glucose
and occult blood tests usually are included on
multideterminant reagent strips to screen urine samples
during routine physical examinations because it is
important to detect excess amounts of these urinary
constituents early.
The test ~trip method is the simplest and most
direct a~say for the presence of a predetermined
analyte. In an assay for glucose, the test area
incorporates an oxidizable indicator dye, like
3,3',5,5'-te~ramethylbenzidine; glucose oxidase; and
peroxidase. In an assay for occult blood, the te~t area
incorporates an oxidizable indicator dye and a
hydroperoxide. In either assay, the test area undergoes
a color transition in response to an interaction between
the predetermined analyte present in the test sample and
the ~lucose oxidase-peroxidase couple, or the
hydroperoxide, to oxidize the tetrame~hylbenzidine. In
a~cordance with the above-de.~cribed method, an
individual can readily determine~ visually, the
concentration o~ the predetermined analyte in a urine
sample by comparing the color of the ~est strip to a
color chart shortly after the test strip i5 dipped into
the te~t sample.
~owever, ascorbic acid or ascorbate ion, when
present in a tes~ sample, seriously interferes in the
above-described oxidation-reduction a~say method for a
MS-1654
- 8 - ~0~78~
predetermined analyte. The most common form of ascorbic
acid typically i~ referred to as Vitamin C. This
vitamin is a vital nutrient and is found in many
naturally-occurring foods, such as fruits and
vegetables. Vitamin C also can be synthesized and is
therefore available as a food additive or in tablet
form. The health benefits of Vitamin C have been known
for some time, as a result, Vitamin C i5 a relatively
popular nutrient. Therefore, Vitamin C is a popular
food additive and a popuiar component of vitamin pills
and the like.
However, the human body generally absorbs
Vitamin C only to the extent necessary to meet short
term needs, The vitamin usually is not stored within
the body, and excess Vitamin C typically is disposed of
through the urinary system. As a result, Vitamin C
co~monly is present in urine samples undergoing clinical
assays.
Ascorbic acid is a reducing agent that can
~0 interfere in clinical assays by reducing the oxidized,
colored form of an indicator dye to the reduced,
colorless form of the dye. ~owever, ascorbic acid can
be oxidized. Therefore, if the ascorbic acid is
oxidized before it can interact with the oxidized
indicator dye, the ascorbic acid cannot act as a
reducing agent and accordingly cannot interfere with the
assay for a predetermined analyte.
Either in the literature or during in-house
screening studies, it has been found that in~luding
certain metal ion complexes in the indicator reagent
composition helps eliminate the ascorbate interference
prablem. However, a metal ion complex also can oxidize
the dye chemically or can demonstrate peroxidase
activity, and behave similarly to peroxidase enzyme or
3S to a pseudoperoxida~e, to catalyze the color-farming
reaction between hydrogen peroxide or a hydroperoxide
MS-1654
9 ~7~6
and an oxidi~able dye. Accordingly, although a metal
ion complex eliminates ascorbate interference, the metal
ion complex may produce false positive assays.
Investigators have found that particular
ferric ion complexes substantially reduce the false
positive assay results attributed to some metal ion
complexes used to eliminake ascorbate intererence.
Ascorbic acid interferences are eliminated because
ascorbic acid is oxidized by ferric ion or by ferric ion
complPxes. Representative publications illustrating the
ferric ion oxidation of ascorbic acid include:
E. Pelizetti et al., "Kinetics and Mechanism
of the Oxidation of Aseorbic Acid by Tris~1,10-
phenanthroline)iron(III~ and Its Derivatives in Aqueous
Acidic Perchlorate Media", ~ 2~ 15, pp. 2898-
2900 (1976), wherein ascorbic acid was reacted with
tris(l,l0-phenanthroline)iron(III) in aqueous
perchlorate over a pH range of one to 3.5, with the rate
of oxidation decseasing with increasing p~;
L.S. Vann, "A Rapid Micro Method for
Determination of Ascorbic Acid in Urine by Ferric
Reduction", Clin. Chem., 11, pp. 979-985 ~1965);
M.M.T. Khan et al., "The Kinetlcs of the
Reaction of Iron tIII) Chelates oE Aminopolycarboxylic
Acids with Ascorbic Acid", J._Am. Chem. Soc., 90, pp.
3386-3389 (1968) and M.M.T. Khan et al., J. Am. Chem.
Soc., 89, p. 7104 (1967), wherein the kinetics of
ascorbic acid oxidation in the presence of ferric and
cupric chelates in the pH range of 1.8 to 3.45 is
discussed;
G~S. Laurence et al., "The Detection of a
Complex Intermediate in the Oxidation of Ascorb.ic Acid
by Ferric Ion", J Chem. Soc. Dalton Trans., pp~ 1667-
1670 (1972);
MS-1654
2~7~6~
-- 10 --
W.C. Butts et al., "Centrifugal Analyzer
Determination of Ascorbate in Serum and Urine with
Fe3+/Ferrozine", Clin. Chem , 2l, pp. 1493-1497 (1975);
L. Pekkarinen, "The Mechanism of the
Autoxidation of Ascorbic Acid Catalyzed by Iron Salts in
Citric Acid Solution", Finn. Chem. Lett., pp. 233-236
(197~);
M. Rimura et al., "Ki~etics and Mechanism of
the Oxidation of L-Ascorbic Acid by Tri~-(oxalato)
Cobaltate(III] and Tris(l,lO-phenanthroline)Iron~III)
Complexes in Aqueous Solution", ~. Chem soc Dalton
Trans., pp. 423-427 (1982); and
A.E. Martell, "Chelates of Ascorbic Acid,
Formation and Catalytic Properties", Ascorbic Acid
Chemistry, Metabolism_and ~ses, Chapter 7~ P.A. Seib and
B.M. Tolbert eds., ~dv. in Chem. Series, ACS, ~ash.,
D.C., pp. 153-178, (1982).
However, the ferric ion-based oxidation of
ascorbic acid described above presents a definite
disadvantage when used to eliminate ascorbic acid
interferen~e in an oxidase-peroxidase coupled reaction
to assay for a predeter~ined analyte. In the oxidation
of a~corbic acid, ferric ion is reduced to ferrous
ion. Ferrous ion is a good reducing agent and can
reduce an oxidized indicator dye, like
tetramethylbenzidine (TMB), from its colored (oxidized)
form to its colorless (reduced) form. Therefore,
although the ferric ion eliminates the primary ascorbic
acid interference, the ferrous ion then produces a
secondary interferinq affect that can result in an
erroneously low assay result.
Accordingly, it would be extremely
advantageous to provide a simple, accurate and
trustworthy method o~ assaying a test sample for low
levels of a predetermined analyte without the primary or
secondary interfering affects attributed to ascorbic
MS-1654
- 11 - 2~8~
acid. Present day test strips for a predetermined
analyte incorporate an indicator reagent composition
including ~ suitable oxidase enzyme; peroxidase enzyme;
and a metal ion complex to reduce primary ascorbate
interferences. Although present day test strips used to
assay for a predetermined analyte are stable and
sensitive, present day test strips still need
improvement in the area of sensitivity. Therefore, it
would be a significant advance in the art o diagnostic
assays if test strips were even more sensitive to a
predetermined analyte in a test sample. It was ~owards
achieving improvements in ascorbate resistance and
sensitivity that the investigations resulting in the
composition, device and method of the present invention
were directed.
Surprisingly and unexpectedly, the composition
and method of the present invention eliminate primary
ascorbate interference and secondary interferences
attributed to the metal ion or metal ion complex by
including a cooxidant selected from the group consi3ting
of bromate iont chlorate ion, perchlorate ion, chromate
ion, organic oxidants like a peroxide, a hydroperoxide
or a N-halo compound, and combin~tions thereof, in the
indicator reagent composition. To achieve the full
advantage of the present invention, bromate ion is
inclu~ed in the indicator reagent composition as the
cooxidan~. It has been found that the cooxidant
oxidize~ the reduced form of the metal ion, e.g.,
ferrous ion, to the oxidized form, e.g., ferric ion,
such that the reduced form of the metal ion is
unavailable to interact with the oxidi~ed form of the
indicator dye. Therefore, the problem of decreased
assay sensitivity attributed to a metal ion or a metal
ion complex included in the indicator reagent
composition is overcome.
MS-1654
2~$~8~
- 12 -
Accordingly, a quantitative assay for a
predetermined analyte can be performed by laboratory
personnel to yield immediate and trustworthy test
results by providing a more accurate assay method in an
easy-to-use form, such as a dip-and-read test strip. In
addition, the test strip method can be performed by an
individual at home to more precisely monitor the level
of a predetermined analyte, like glucose or occult
blood~ in a test sample, like blood or urine, or to
monitor the success of the medical treatment the
individual is undergoing.
As will be described more fully hereinafter,
the me~hod of the present invention allows the fast,
accurate and trustworthy as ay for a predet~rmined
analyte by utilizing a test strip that includes a test
pad comprising a suitable carrier matrix incorporating
an indicator reagent composition of the present
invention, said indicator reagent composition eomprising
an indicator dye, a redox mediator, a metal ion complex
and a cooxidant. If the predetermined analyte, like
glucose, is capable of in~eracting with an oxidase
enzyme, the redox mediator comprises a suitable oxidase
enzyme and a peroxidase enzyme. If the predetermined
analyte, like occult blood, demonstrates peroxidative
activity, the redox mediator comprise~ a
hydroperoxide. The cooxidant is selected from the group
consisting of bromate ion, chlorate ion, perchlorate
ion, chromate ion, an organic oxidant like a peroxide, a
hydroperoxide or a N-halo compound, and combinations
thereof.
Prior to the present invention, no known
method of assaying a test sample for a predetermined
analyte in an oxidation-reduction coupled reaction
included an indicator reagen~ composition comprisin~ an
indicator dye; a redox mediator; a metal ion complex;
and a cooxidant selected from the group consisting of
MS~1654
- 13 - 2~7~6
chlorate ion, bromate ion, perchlorate ion, chromate
ion, an organic oxidant like a peroxide, a hydroperoxide
or a N-halo compound, and combinations thereof.
Although dry phase test strips including an indicator
dye, a redox mediator and a metal ion complex have been
used previously, dry phase test strips incorporating
such compositions demonstrated a tendency to provide
erroneous assay results because of secondary
interferences attributed to the metal ion of the metal
ion complex. Accordingly, such erroneous assays
decreased the sensitivity of the test strip to the
predetermined analyte in the test sample. In contrast,
the indicator reagent composition of the present
invention essentially eliminates both the primary
ascorbate interference and, surprisingly and
unexpectedly, the secondary interferences attributed to
the metal ion complex. Consequently, the improved
indicator reagent composition enhances the sensitivity
of the assay, thereby providing a more accur te and
trustworthy as~ay for a predetermined analyte by an
oxidation-reduction based chemistryO
Several other attempts at achieving the above
mentioned ~oals of increased assay sensitivity and
decreased ascorbate interference are found in prior
patent~ and publications. For example, with re~ard to
ascorbate interferences in glucose assays, methods have
ranged from filtering the ascorbate from the test sample
before the test sample contacts the test reagents to
using an enzyme that interacts with the ascorbate.
Accordingly, Canadian Patent No. 844~564 to Dahlquist
disclosed a test device for glucose assays that includes
a porous area to receive the test sample. The sample-
receiving area doe~ not include assay reagents, but
comprises an ion exchange material that absorbs the
3~ aecorbate present in the test sample.
MS-1654
2~7~66
- 14 -
U.S. Patent No. 4,168~205 to Danninger et al.
described incorporating ascorbate oxidase into the test
reagent formulation to enzymatically oxidize the
ascorbate present in the sample to dehydroascorbate, a
compound that does not adversely affect the assay.
Japanese Patent Publication No. 55757 ~1983) to Fuji
Zoki Seiyaku K.K. disclosed pretreating a test sample
with a metal chelate of a ligand, such as
ethylenediaminetetraacetic acid or
diethylenetriaminepentaacetic acid, to eliminate
ascorbate, then assaying the test sample for
cholesterol, glucose or uric acid.
Ku, in U.S. Patent No. 3,411,887, described
the elimination of ascorbate interference with reagE~nt
compositions that rely on enzymatic cxidizing
substances, such as glucose oxidase, by using an
ascorbate '~trapping system." The "trapping system"
utilizes a heavy metal ion that has an oxidation-
reduction potential falling between a redox indicator
dy~ and ascorbate. Suitable h~avy metal compounds cited
as examples include cobalt, iron, mercury and nickel.
Another publication disclosing the complexing and
oxidation of a~corbate using cobalt i.s G. Braga~nolo,
Ann. Chim. A~plicata.~ 31, pp. 350-368 (1941), teaching
that solutions of ascorbic acid were oxidized by air in
the presence of cobalt metal. Also, similar activity
has been reported for Co(NH3)6Cl3 by T. Iwasaki, Journal
of the Chemlcal Society_of Japan, _, pp. 820-826
(1942).
U.S. Patent No. 4,310,626 to Burkhardt et al.
described the use of ammonium cobalt(III) complexes to
reduce ascorbate interference in assays for
peroxidatively active substances. Burkhardt et al.
disclose compositions co~nprising an organic
hydroperoxide and a suitable ind;cator, such as
MS-1654
2~7~6~
- 15 ~
3,3',5,5'-te~ramethylbenzidine, together with ammonium
cobalt(III) complexes, such as Co(NH3)6Cl3.
Copper ions also have been used to eliminate
ascorbate interference from assays. For example, I.
Pecht, et al., in "The Copper-Poly-L-Histidine
Complex: I. The Environmental Effect of the
Polyelectrolyte on the Oxidase Activity of Copper Ions",
J. Am. Chem. Soc,, 89:1587 (1968), disclosed that
ascorbate can be oxidized by oxygen and a copper
catalyst. N.A. Vengerova et al. in the publication,
"The Ascorbate-Oxidase Activity of the Cu~2-Poly-4-
Vinylpyridine Complex Alkylated with Bromoacetic Acid",
~ok~ V--d., A 13r NoO 11~ pp. Z509-2517 (1971)
(~ranslated by K.A. Allen)l disclosed a method of
synthesiæing carboxymethyl derivatives of poly-4-
vinylpyridine and taught that a Cu(II) polymer complex
increase3 ascorbate oxidizing activity relative to
copper ions alone. Other references relating to Cu(II)
oxidation of ascorbate include: Z. Sun et al., "Studies
on Functional Latices: C~talytic Effects of ~istamine-
Containing Polymer-latex-copper (II) Complex on the
Oxidation of Ascorbic Acid", Macromolecule~, 19:984-987
(1986); and Y.I. Skurlator et al., "The Mechanism of
Ascorbic Acid Oxidation by Cu(II)-Poly-4-Vinylpyridine
Complexes", European Po~ymer Journ~l, 15s811-815 (1979).
y.s. Patent No. 4,288,541 to Magers et al~
disclo~ d the use of mercuric ion complexes, such as
mercuric sarcosinate, to impart ascorbate resis~ance to
a glucose oxidase-based assay for glucose. In addition
to the above patents and publications, the problem of
ascorbate intererence in glucose a~says i9 discussed
in:
H. Gifford, et al., J. Amer. Med. Assoc., 178,
pp. 14g-lS0 (1961);
P. O'Gorman, e~ al., B_lt Med J., pp. 603-
606 (1960);
MS-1654
2~678g6
- 16 -
R. Brandt, et al., Clin. ChemO Acta., 51, pp.
103-104 (1974); and
R. Brandt~ et al., Am. ~. Clin. Pathol., 68,
_. _
pp. 592 594 (1977).
Other methods of eliminating ascorbate
interference in analytical determinations of
predetermined analyte include, for example, ~est German
Patent No. 29 07 628, directed to a wet phase
urinalysis, whereby a urine sample is pretreated with an
oxidant to remove ascorbate prior to the assay. The
oxidants disclosed as useful are sodium iodate/ sodium
periodate, calcium hydrochlorite, potassium triiodide,
sodium hydrochlorite, chloroamine and
bromosuccinimide. Also, European Patent Application
00370S6 described the use of iodate in diagnostic
methods to avoid interference by reducing agents,
includin~ ascorbic acidO
U.S. Patent No. 4,587,220, to Mayambala-
Mwanika et al., disclosed the use of a chelated ferric
ion to eliminate ascorbate interference in an assay for
a peroxidatively active substance. Mayambala-Mwanika
disclosed that a ferric chelate, like the ferric chelate
of N~(2-hydroxyethyl)ethylenediaminetriacetic acid (Fe-
HED~A), eliminated ascorbate interference and did not
produce a false positive test for a peroxidatively
active com~ound.
Ismail et al.l in U.S. Patent No. 49755,472,
disclosed a stable test pad to assay for a
peroxidatively active substance that includes a carrier
matrix impregnated with 1,4-diisopropylbenzene
dihydroperoxide and a benzidine indicator in a molar
ratio of hydroperoxide to indicator of from about 0.9 to
3Ø A ferric chelate also can be included to provide
ascorbate resistan~e. The test pad was stable during
storage and does not lead to false positlve tests on
other test pads present on a multideterminant test
MS-1654
- 17 - 2~78~
strip, such as glucose test pad based on a
peroxidase/potassium iodide indicator.
In contrast to the prior art, and in contrast
to the presentLy-available commercial test strips, the
S composition, method and device of the present invention
demonstrate increased sensitivity in an assay to detect
or measure the concentration of a predetermined analyte
in a test sample, wherein the predetermined analyte
either is capable of interacting with an oxidase enzyme
or demonstrates peroxidase ac~ivityO The method of the
present invention utilizes an indicator reagent
composition that al effectively eliminates primary
ascorbate interferences by including a metal ion
complex, and b) effectively eliminates secondary
interferences attributed to the metal ion complex by
including a cooxidant selected from the group consisting
o bromate ion, chlorate ion, perchlorate ion, chromate
ion, organic oxidants like a peroxide, a hydroperoxide
or a N-halo compound, and combinations thereof.
For example, bromate ion is used in analytical
chemistry as a titrimetric reagent. In acidic media,
bromate ion is almost as powerful an oxidizing agent as
permanganate ion. In the presence of strong reducing
agents, bromate ion (BrO3~) is reduced to bromide ion
(Br ). However, bromate ion is capable of oxidi2ing
bromide ion to bromine tBr2) as demonstrated in the
following equations (1) and (2):
BrO3 + 5~+ ~ 6e --------- Br~ + 3H20 (1)
BrO3 + SBr + 6~ 3Br2 + 2H20 (2)
I.M. Kolthoff et al., in Volumetric Analysis, Vol. III,
Titration Methods: Oxidation-~eduction Reactions,
Chapter XII, Interscience Publishers, N.Y., N.Y. (1971),
teach that bromide ion is formed in the first step of
MS-1654
- 18 ~ 7 ~ ~ ~
the reaction (Eq. 1), then the bromide ion reacts with
excess bromate to yield free bromine (Eq. 2) in a pH-
dependent reaction sequence~ From E~s. (1) and (2), it
is demonstrated that acidic condition~ are necessary for
the reaction to proceed. Similarly, it is known that
chlorate ion (C103-) does not demonstrate oxidi~iny
properties in a neutral or alkaline solution, whereas
chlorate ion demonstrates strong oxidi~ing properties in
acidic solutions due to the presence of chloric ~cid
(HC103).
The bromate ion oxidation of reduced metal
ions also has been described. For example, the bromate
ion oxidation of ferrous ion, i.e., lron(II), has been
described in:
lS J.P. Birk, "Mechanism of the Bromate Ion
Oxidation of Aquoiron(II)", Inorq. Chem., 12, pp. 2468-
2472 (1973);
J.P. Birk et al., "Mechanism of the Reduction
of Bromate Ion by Cyano(bipyridyl) Iron(II) Complexes",
Inor~. Chem., 17, pp. 1186-1191 (1978): and
S.G. Kozub, "Kinetics and Mechanisms of the
~romate Oxidations of Substitution - Inert IrontII)
Complexes in ~cidic Aqueous Solution," Ph.D.
Dissertat~on, Xerox University Microfilms, ~nn Arbor,
(1975)
In each above-identified publication, the
reaction between bromate ion and ferrous ion wa~ studied
at very acidic conditions in perchloric acid.
Furthermore, it is known that bromate ion does not
oxidize ascorbic acid at an appreciable rate in the
essentially neutral pH range of from 5 to 7.
U.S. Patent Application Serial No. 337,620,
filing date April 13, lg89 and commonly assigned to the
assignee of the present invention, describes the
elimination of ascorbate interference from clinical
assays by utilizing a copper(II) complex including a
MS-1654
2~7~
-- 19 --
water-soluble polymerO In addition, a cooxidant is
included to oxidize the copper(I) ion back to copper(II)
after the interaction with ascorbate. The cooxidant can
be an organic oxidant, like a peroxide or a N-halo
compound, or an inorganic oxidant, like chromate,
mercuric ion, thallium(III1 ion, ceric(IV) ion,
manganese(III) ion, bromate or iodate. U~S. Patent
Application Serial No. 337,620 does not teach or suggest
any metal ion other than copper(II) as the oxidant to
eliminate ascorbate interference.
As will be demonstrated more fully
hereinafter, it has been found that a cooxidant selected
from the sroup consisting of bromate ion, chlorate ion,
perchlorate ion, chromate ion, organic oxidants like a
peroxide, a hydroperoxide or a N~halo compound, and
combinations thereof, when included in an indicator
reagent composition of the present invention having an
essentially neutral pH~ oxidizes the reduced form of a
metal ion, said metal ion included in the composition to
eliminate primary ascorbate interference, back to the
oxidized form of the metal ion. Such a result is both
surprising and important. The result is surprising
because of the p~ range wherein the cooxidant, like
bromate ion or chromate ion, oxidizes the metal; and the
result is important because the metal ion, originally
included in t~e composition to el~minate primary
ascorbate interference, itself becomes a secondary
interferent when the reduced form of the metal ion
interacts with the colored, oxidized form of the
indicator dye to reduce the dye to its colorless,
reduced form. Accordingly, because of this secondary
interference, the indicator dye apparently does not
undergo a full color transition in response to the
concentration of the predetermined analyte in the test
sample. Therefore, an erroneously low assay result for
the predekermined analyte is providedO
MS-1654
~o 20~78~
However, the composition, method and device o~
the present invention provide an accurate assay for a
predetermined analyte that is capable of interacting
with an oxidase enzyme or that exhibits peroxidase
activity. Surprisingly, the method and composition of
the present invention essentially eliminate both the
primary and the secondary interferences attributed to
ascorbate present in the test sample. Hence, in
accordance with the method o the present inventioni new
and unexpected results are achieved in the dry phase
test strip assay of blood9 urine and other test samples
for a predetermined analyte by utilizing an indicator
reagent composition that includes a metal ion complex to
eliminate primary ascorbate interference and a cooxidant
selected from the group consisting of bromate ion,
chlorate ion, perchlorate ion, chromate ion, organic
oxidants like a peroxide, a hydroperoxide or a N-halo
compound, and combi~ations thereof to eliminate
secondary interferences attributed to the reduced form
of the metal ion of the metal ion complex.
SUMMARY OF THE INVENTION
In brief, the present invention is directed to
a new and improved composition, test device and method
of determining the presence or concentration of a
predetermined analyte in a test sample, wherein the
predetermined analyte either a) is capable of
interacting with an oxidase enzyme or b) demonstrates
peroxidase activity. The device includes a test pad
compri~ing a suitable carrier matrix incorporating an
indicator reagent composition capable of interacting
with the predetermined analyte to produce a detectable
respon~e. For home use, the indicator reagent
composition produces a visually detectable response.
For laborato~y use, the indicator reagent composition
produces a response that i9 detectable visually or by
MS-1654
- 21 ~ 78~
instrument. The carrler matrix of the test pad
comprises a bibulous material, such as filter paper; a
nonbibulous material, such as a layer or film of a
polymerized material; or a combination thereof. An
indicator reaqent composition is incorporated into the
carrier matrix, and the carrier matrix then holds the
indicator reagent composition throu~hout the carrier
matrix while maintaining carrier matrix penetrability by
the predetermined analyte of the test sample.
More particularly, the present invention is
directed to a method of assayins blood, urine or other
liquid test samples for a predetermined analyte by
utilizing a new and improved indicator reagent
composition. The predetermined analyte is a compound
capable of interacting with an oxidase enzyme, such as
glucose, cholesterol, uric acid, alcohol or
triglycerides; or a compound that demonstrates
peroxidative activity, such as hemoglobin, i.e. occult
blood. It has been demon~trated that an indicator
reagent composition comprising: (a~ an indicator dyet
like a redox indicator, capable of undergoing a color
transition in response to a predetermined analyte; (b) a
redox mediator, either including an oxidase enzyme and
peroxidase or including a hydroperoxide; (c) a metal ion
complex; and (d) a cooxidant selected from the group
consisting of bromate ion, chlorate ion, perchlorate
ion, chromate ion~ an organic oxidant like a peroxide, a
hydroperoxide or a N-halo compound, and combinations
thereof, has effectively eliminated both primary
ascorbate interferences and secondary interferences
attributed to the metal ion complex, and, therefore, has
demonstrated an increased sensitivity to the
predetermined analyte.
The metal ion complex included in the
indicator reagent composition effectively eliminates the
primary interfering affects of ascorbate present in the
MS-1654
- 22 - 2~8~
test sample by oxidizing the ascorbate. In this
oxidation-reduction reaction, the metal ion of the metal
ion complex is reduced. The cooxidant, like bromate
ion, included in the composition then oxidizes the
reduced form of the metal ion, such that the reduced
form of the metal ion is not available to reduce the
oxidi~ed form of the indicator dye to :its colorless
reduced form. Accordingly~ the color transition
resulting from contact ~etween the test pad
incorporating the indicator reagent cornposition and the
test sample is a true, not an apparent, color
transition, and the color transition can be accurately
correlated to the amount of predetermined analyte in the
test sample.
In accordance with an important feature of the
present invention, a more accurate and more reliable
assay for a predetermined analyte in a liquid te~t
sa~ple is achieved because the interfering affects of
ascorbate ion are eliminated by the metal ion complex,
and the full color tr~nsition is detected because the
cooxidant oxidizes the reduced form of the metal ion to
the oxidized form of the metal ion before the reduced
form of the metal ion can interact with the colored,
oxidi~ed form of the indicator dye. By utilizing the
indicator reagent composition of the present invention
in clinical test methods, the qualitative or
quantitative assay for a predetermined analyte, such as
gluco~e or hemoglobin, in urine or other test samples is
more accurate because the full color transition of the
indicator reagent composition in response to the amount
of predetermined analyte in the test sample is
detected. The color transition, and therefore the
assay, is free of interference~ attribu~ed to ascorbate
ion and to the reduced form of the metal ion present in
the metal ion complex.
MS-1654
2~6~6
- 23 -
Therefore, one important aspect of the present
invention to provide a simple, accurate and reproducible
method of assaying blood, urine and other test samples
for a predetermined analyte, wherein the predetermined
S analyte either is capable of interacting with an oxidase
enzyme or is capable of exhibiting peroxidase
activity. The method utilizes an indicator reagent
composition that eliminates primary and secondary assay
interferences attributed to ascorbate, and therefore
provides increased sensitivity to the predetermined
analyte.
The present method for assaying blood, urine
or other test liquids for a predetermined analyte
utilizes an indicator reagent composition comprising an
indicator dye; a redox mediator either comprising a) an
oxidase enzyme and peroxidase or b) a hydroperoxide: a
metal ion complex; and a cooxidant selected from the
group consisting of bromate ion, chlorate ion,
perchlorate ion, chromate ion, an organic oxidant like a
peroxide, a hydroperoxide or a N-halo compound, and
combinations thereof wherein the primary interfering
affects of ascorbate and the secondary interfering
affects of the reduced form of the metal ion complex are
essentially eliminated.
The indicator reagent composition, upon
contact with a test sample, interacts with the
predetermined analyte in the test sample and undergoes a
detectable or measurable color transition to establish
the presence or concentration of the predetermined
analyte in the test sample. The composition, method and
test device of the present invention provide an assay
that is sensitive to low concentrations of the
predetermined analyte and provide accurate assay results
for the predetermined analyte.
MS-16S4
2~67~
- 24 -
BRIEF DESCRIPTION OF THE DRAWINGS
The above and other objects and advantages and
novel features of the present invention will become
apparent from the followin~ detailed description of the
preferred embodiments of the present invention in
conjunction with the accompanyin~ figures:
~ IG. 1 is a series of plots of absorbance at
265 nm (nanometers) (A265) vs. time (seconds)
illustrating the increased rate of ascorbic acid
oxidation by potassium bromate (KBrO3~ as monitored by
the diminishing ascorbic acid peak at 265 nm, wherein
the concentration range was varied from O mM to 10 mM
(millimolar) KBrO3 at pH 6.5 in the presence of 25 ~M
(micromolar) FelIII)-HEDTA;
FIG. 2 is a graph of the rate constant of
ascorbic acid oxidation, (k (sec -1)) vs. potassium
bromate over the ooncentration range of O mM to 10 mM
KBrO3 at pH 6.5 and in the pre~ence of 25 ~M Ee(III3-
HEDTA; and
FIG. 3 is a series of plots of A265 vs, time
illustrating the rate of ascorbic acid oxidation by 0.5
mM potassium broma~e and Fe(III)-H~DTA over the
concentration range of O ~M to 50 uM Fe(III)-HEDTA at pH
6.5.
DETAILED DESCRIPTION OF THE I~ENTION
In accordance with the method of t~e present
invention, the qualitative or quantitative assay for a
predetermined analyte, such as glucose, cholestero},
uric acid or occult blood~ in blood, urine and other
test samples i~ accomplished by utilizing an indicator
reagent composition comprising an indicator dye; a redox
mediator; a metal ion complex; and a cooxidant selected
from the group con~isting of bromate ion, chlorate ion,
perchlorate ion, chromate ion, an organic oxidant like a
peroxide, a hydroperoxide or a N-halo compound, and
MS-1654
6 ~
- 25 -
combinations thereof. In accordance with an important
feature of the present inventioni the predetermined
analyte is either (a) a compound capable of interacting
with an oxidase enzyme, such as glucose, chole~terol,
alcohol, uric acid or triglycerides, or (b) a compound
that exhibits peroxidase a~tivityr such as hemoglobin
(i.eO, occult blood) and myoglobin. Therefore, the
redox medi tor of the indicator reagent composition
comprises, respectively, either (a~ a suitable oxidase
enzyme and peroxidase, or (b) a hydroperoxide.
The indicator reagent composition of the
present invention essentially eliminates the primary
interfering affects of ascorbic acid present in the test
sample and the secondary interfering affects attributed
to the metal ion complex that is included in the
indicator reagent composition to interact with the
ascorbic acid. Therefore, the indicator dye, after
contacting a test sample including the predetermined
analyte, undergoes a full color transition in respon~e
to an interaction between the predetermined analyte and
the redox mediator.
The metal ion complex is included in the
indicator reagent composition to oxidize ascorbic acid
2re~ent in the test sample~ and therefore to eliminate
primary ascorbate interferences. U.S. Patent No.
4,587,220 to Mayambala-Mwanika et al. di~closes the use
of particular ferric ion chelates to substantially
eliminate primary ascorbate interferences. ~owever,
problems nevertheless still exist in present day methods
and devices to assay for predetermined analytes capable
of interacting with an oxidase enzyme or capable of
exhibit.ing peroxida~e activity. For example, in the
oxidization of ascorbic acid/ the metal ion of the metal
ion complex is reduced, e.g., a Eerric ion chelate is
reduced to a ferrous ion chelate. Ferrous ion is a
reducing agent of sufficient ~trength to interact with
MS-1654
2$~7~6~
- 26 -
the oxidized form of the indicator dye, i.e~, the
colored form, to reduce the oxidized form o the dye to
its reduced form, i.e., the colorless form. ThereEore~
an erroneously low assay results because a portion of
the color transition is reversed.
Surprisingly and unexpectedly, it has been
found that by including a suitable cooxidant, like
bromate ion, in the indicator reagen~ composition, the
ferrous ion i5 oxidized to ferric ion before the ferrous
ion can interact with the oxidized form of the indicator
dye, thereby precluding an interfering interaction
between the ferrous ion and the oxidi~ed indic~tor
dye. Therefore, the color transition resulting from the
interaction between the predetermined analyte and the
indicator dye, mediated by the redox mediator, is more
spectacular. Accordin~ly, the accuracy and the
sensitivity of the assay to a low concentration of a
prede~ermined analyte are increased.
~he improved accuracy and increased
sen~itivity to low levels of a predetermine~ analyte
afforded by the method of the present.invention are
especially useful in urine assays ~or glucose or for
occult blood. A commercially-useful urine assay for a
predetermined analyte includeq a stable indicator
reagent composition, i~ sen~itive and preferably i5
resistant to primary ascorbic acid in~er~erence and
secondary in~erferences attributsd to ascorbic acid or
~o the elimination of ascorbic acid from the test
sample.
A~ previously discussed, ascorbic acid and the
ascorbate ion are common interferents in diagnostic
tests based on redox indicator dyes. Ascorbic acid
interference in the assay of urine for glucose and
occult blood is well known in the art and preferably is
eliminated. A~corbic acid interferes with the oxidation
of the indicator dye, and therefore ascorbic acid in a
MS-1654
~78~fi
- 27 -
test sample prQduces an apparent negative result for a
predetermined analyte. "Ascorbate resistance" therefore
is defined as a negligible interference with the color
transition of the indlcator dye when a urine sample
contains as much as about 200 mg (milligrams) ascorbic
acid per deciliter (dL) of sample.
The elimination of as orbate interference in
the assay for a predetermined analyte is clinically
important because detecting a low concentration of the
predetermined analyte in the test sample can signify a
diseased or damaged condition that should be
investigated further. Accordingly~ and as will be
discussed more fully hereinafter, the method and device
of the present invention accurately assay for a low
concentration of a predetermined analyte in a test
sample. The method and device of the present invent:ion
utilize an indicator reagent composition that undergoes
a color transition only in response to the concentration
of the predetermined analyte in the test sample, thereby
providing a sensitive and reliable assay for a
predetermined analyte. Surprisingly and unexpectedly,
it has been found that including a suitable cooxidant in
an indicator reagent composition further comprising an
indicator dye, a redox mediator and a metal ion complex
substantially increases the accuracy and sensitivity of
the assay for a predetermined analyte by essentially
eliminating the primary interfering a~fects attributed
to ascorbate ion and the secondary interfering affects
attributed to metal ions present in a reduced form.
It will become apparent that the method and
device of the present invention also can be used to
determine the presence or quantitive concentration of a
predetermined analyte in blood plasma or serum, urine,
feces, and gastrointestinal contents; and more
generally, the predetermined analyte concentration of
many other biological Eluids and semisolids as well. In
MS-1654
~7~
- 28 -
general, any aqueous test sample, or test sample that is
soluble in an aqueous solvent, can be assayed. To
achieve the full advantage of the present invention, the
composition of the present invention i5 employed in a
dry phase test strip to determine the presence or
concentration o a predetermined analyte in urine or
other test samples, wherein the predetermined analyte
either is capable of interacting with an oxidase enzyme
or is capable o exhibiting peroxidase activity.
The method and test device utilizing the
composition of the present invention provide a more
accurate, trustworthy and clinically significant assay
for a predetermined analyte because the indicator dye is
oxidized to undergo a color transition in re~ponse to
the amount of the peroxidatively active substance
present in the test sample. The degree and intensity of
~he color transition are not diminished due to the
presence o ascorbic acid or to the presence o~ reduced
metal ions~ both of which reduce the colored, oxidized
form of the indicator dye to its colorle~, reduced
form. Accordingly, assay sensitivity is increased, and
a fast, arcurate and trustworthy method of assaying for
a predetermined analyte, performable at home or in the
laboratory to yield essentially immediate assay results,
is achieved.
The method of the present invention utilizes
the ability of a predetermined analyte either to
interact with an oxidase enzyme to generate hydrogen
peroxide, that in turn interacts with a peroxidase to
release oxygen, or to interact with a hydroperoxide to
release oxygen. In either case, the oxyqen then
oxidizes an indicator dye. The oxidation of the
indicator dye results in a color transition of the
indicator reagent composition, with the degree and
intensity o the color transition being directly
proportional to the concentration of the predetermined
MS-1654
2 ~
- ~9 -
analyte in the test sample. Accordingly, the indicator
reagent composition of the present invention includes a
redox mediator, i.e., either an a) oxidase enzyme and
peroxidase or b) a hydroperoxide, and an indicator dye,
wherein the indicator dye undergoes a color transition
upon conversion to its oxidized form by oxygen formed
from an interaction between the redox mediator and a
predetermined analyte present in the test sample.
The indicator reagent composition also
includes a compound to eliminate primary ascorbate
interference from the assay for the predetermined
analyte. In accordance with the present invention, the
ingredient included to eliminate ascorbate interference
preferably is a metal ion complex. However, as will be
discussed more fully hereinafter, a water-soluble metal
ion salt also can be used to eliminate the primary
ascorbate interferenee. The metal ion is present in its
oxidized form, ~uch as ferric ion, for example, and is
capable of interacting with, and oxidizing, ascorbate to
eliminate ascorbate interference. Consequently, the
metal ion is reduced to its reduced form, i.e. ferrous
ion. The ferrous ion however can interact with the
colored, oxidized form of the indicator dye to
regenerate ferric ion and the colorless, reduced form of
the indicator dye. Therefore, a portion of the color
transition is reversed and an erroneously low assay
re~ults.
Consequently, and in accordance with an
important feature of the present invention, the
indicator reagent composition also includes a cooxidant
selected from the group consisting of bromate ion
(BrO3 ), chlorate ion (Cl03-), perchlorate ion (C104-),
chromate ion (CrO4~2), an organic oxidant like a
peroxide, a hydroperoxide or a N-halo compound, and
combinations thereof to effectively and rapidly
reoxidize the ferrous ion to ferric ion, thereby
MS-1654
2~78~
- 30 ~
precluding an interaction between the ferrous ion and
the oxidized form of the indicator dye. Therefore, the
full color transition is detected and measured to
provide an accurate and reliable assay for a
predetermined analyte.
As will be discussed more fully hereinafter,
the indicator reagent composition of the present
invention also can include a buf~er compound to provide
a p~ in the range of from about 5 to about 7. Within
this pH range, the color transition resulting from
oxidation of the indicator dye is the most spectacular
and differentiable~ However, it is unexpected for
bromate ion, chlorate ion or perchlorate ion to interact
with a redured metal ion at this sli~htly acidic to
essentially neu~ral pH to regenerate the oxidiz*d form
of the metal ion and to generate an innocuous reduction
product t like bromlde ion. The prior art teaches that
bromate ion, chlorate ion and perchlorate ion act as
oxidizing agents in very acidic media, su~h as media
having a pH of below about 4
The following unbalanced reactions illustrat~
and ~ummarize the interactions that occur when a tes~
sample including a predetermined analyte contacts a test
device including an indicator reagent composition of the
present invention. For illustration purposes, the
predetermined analyte is glucose; the metal ion complex
is the of ferric ion chelate N-(2-
hydroxyethyl)ethylenediaminetetraacetic acid (Fe(IIIj-
HEDTA~; and the cooxidant is bromate ion. The term
"Ind. dye" refers to an indicator dye, and the terms
"ox" and "red" are abbreviations for the oxidize~ form
and the reduced form of ~he dye. Fe(II)-HEDT~ is the
reduced form, or ferrous form, of Fe(III)-H~DTA.
MS-1654
2~6~g~
Glucose + Oxygen (2) ~ D_
Hydrogen Peroxide (H202) + Gluconi~ Acid (3)
H20~ + Ind.dye (red.) (colorless) Peroxidase ~D-
Ind.dye (ox.) (colored) + H20 (4)
Ascorbic acid ~ Ind.dye (ox.)~Dehydroascorbate I Ind.dye (red.) (5)(colored) (colorless)
Fe(III) HEDTA ~ Ascorbic Acid-q~ Fe(II)-HEDTA ~ Dehydroascorbate (6)
Fe(II)-HEDTA + Ind.dye ~ox.)J_Fe(III)-HEDTA + Ind.dye (red.) (7)
(colored) (colorless)
3romate (8rO3 ) + Fe(II)-HEDTA ~ 8romide (Br~) ~ Fe(III)-HEDTA (8)
Equation5 (3) and ~4) illustrate the reaction
scheme for the chromogenic assay for glucose, wherein
the degree and intensity of the color change occurring
in Equation (4) are proportional to the amount of
glucose in the test sample. Equation (5) illustrates
ascorbic acid interacting with the oxidi~ed indicator
dye to diminish the color ~ransition and provide a false
negative assay re~ult or otherwise interfere with the
assay. Equation (6) shows the ferric ion chelate,
Fe(III)-HEDTA, eliminating the primary ascorbate
interference by oxidizing ascorbic acid to the innocuous
dehydroascorbate. Equation (7) illus~rates the
secondary ascorbate interference that results when the
reduced form of the metal ion complex (Fe~ HEDTA)
in~erac~s with the oxidized form of the indicator dye to
provide the reduced form of the indicator dye, and
therefore diminish the degree and intensity of the color
transition. E~uation (8) illustrates bromate ion
interactinq with the ferrous ion of reduced form of the
metal ion complex (Fe(II)-HEDTA) to eliminate secondary
ascorbate inter~erences. Equation (8) shaws that
bromate ion is reduced to the innocuous bromide ion and
that the noninterfering Fe(III) HEDTA is regenerated.
MS-1654
~)~6786~
- 32 -
Accordingly, by including a metal ion complex and a
suitable cooxidant, like bromate ion, in the indicator
reagent composition, interferences attributed to
ascorbate (primary interference) and to the metal ion
complex added to eliminate asoorbate (secondary
interference) are essentially eliminated.
The indicator dye included in the indicator
reagent composition is limited only in that the
indicator dye is capable of undergoing a detectable
response, and preferably a chromogenic response, in the
presence of a predetermined analyte and a redox
mediator, such as an oxidase-peroxidas2 couple or a
hydropProxide Accordingly, the indicator dye
preferably is a redox indicator that undergoes a color
transition upon conversion from its reduced form to its
oxidized form by the interaction between the
predetermined analyte and the redox media~or. The
indicator dye should be sufficiently stable such that
both a predetermined analyte and a redox mediator are
present before a color transition occurs. To achieve
the full advantage of the present invention, the
indicator dye undergoes a color transition through
various detectable and measurable degrees and
intensities of color such that the degree and intensity
of the color transition can be correlated to the
concentration of a predetermined analyte in a test
sample.
Several indicator ~yes are suitable for use in
the composition of the present invention, and generally
include compounds that are oxidized relatively easily to
yield deeply-colored oxidation products. Suitable
classes of indicator dyes include, but are not limited
to, the benzidine-type indicator compounds and the
heterocyclic azine indicator compounds. Examples of the
heterocyclic azine indicator compounds include, but are
not limited to, bis-(N~ethylquinol 2-one)-azine and (N-
MS-1654
2~7~6
- 33 -
methylbenzthiazol-2-one)-(1-ethyl-3-phenyl-5-methyl-
triazol 2-one)-azine. The benzidine-type indicator
compounds include, but are not limited to, for example,
benzidine, o-tolidine; 3~3'~5,5'-tetra(lower
alkyl)benzidine; o-dianisidine; 2,7-diaminofluorene; and
mixtures of these and other suitable indicator dyes.
The expression "lower alkyl", as used above, is defined
as an alkyl moiety having from one to about 5iX carbon
atoms, including methyl, ethyl, n-propyl~ isopropyl and
the various butyl, pentyl and hexyl isomers. To achieve
the full advantage of the present invention, the reclox
indicator, 3,3',5,5'-tetramethylbenzidine (TM~), is
included in the indicator reagent composition.
The indicator dye usually is present in the
indicator reagent composition in a concentration of from
about 5 mM (millimolar, or millimoles of indicator dye
per liter of indicator reagent composition) to about 60
mM, and preferably in a concentration of from about 20
mM to about 40 mM. It should be understood that the
amount of indicator dye in the indicator reagent
composition can be less than about 5 mM, or greater than
about 60 mM, depending upon ~he intensity of the color
transition that a particular indicator dye undergoes
upon oxidation. In general, the amount of indicator dye
included in the indicator reagent composition is limited
only in that the indicator dye undergoes a detectable
color transition for a qualitative assay or, for a
quantitative assay, undergoes a measurable color
transition in proportion to the amount of predetermined
analyte in the test sample.
In accordance with another important feature
of the present invention, the indicator reagent
composition also includes a redox mediator. If the
predetermined analyte is a compound capable of
interacting with an oxidase enzyme, then the redox
mediator includes a~ an oxidase enzyme that specifically
MS-1654
- 34 -
interacts with the predetermined analyte and b)
peroxidase enzyme If the predetermined analyte is a
compound capable of exhibiting peroxidase activity, then
the redox mediat.or includes a hydroperoxide.
In the assay for a predetermined analyte that
exhibits peroxidative activity, like hemoglobin~ the
predetermined analyte is capable of interacting with a
redox mediator comprising a hydroperoxide~ As a result
of this interaction, the indicator dye is oxidized and
undergoes a color transition proportional to the amount
of predetermined an~lyte in the test sample. If the
predetermined analyte present in the test sample
exhibits peroxidative activity, i.e., behaves similar to
the enzyme peroxidase, the predetermined analyte
catalyzes the oxidation of the indicator dye.
Accordingly, a hydroperoxide included in the
indicator reagent composition of the present invention
as a redox mediator for a predetermined analyte that
exhibits peroxidative activity should be sufficiently
stable such that free oxygen is not liberated in the
absence of the predetermined analyte. In addition, the
hydroperoxide should pos~ess a sufficiently low vapor
pre~sure such that the hydroperoxi~e does not evaporate,
or sublime, from the indicator reagent composition
Z5 during storage, or after the indicator reagent
composition is incorporated into a carrier matrix of a
test pad of a dry phase test strip. Furthermore, the
hydropProxide should demonstrate a sufficient
sensitivity to detect 1 part of the predetermined
analyte, like hemoglobin, in one trillion parts of test
sample, such as in the assay of urine for occult blood.
~ herefore, a hydroperoxide useful in the
indicator reagent composition of the present invention
is selected from among the many well known
hydroperoxides. A suitable hydroperoxide is capable of
interacting with a predetermined analyte in the presence
MS-1654
2~7~
- 35 -
of a suitable indicator dye to produce a detectable
response, such as a color transition or a change in the
amount of light absorbed or reflected by the test
sampleO Organic hydroperoxides are preferred. Specific
examples of suitable hydroperoxides include, but are not
limited to, cumene hydroperoxide; t-butyl hydroperoxide;
diisopropylbenzene hydroperoxide; l-hydroxycyclohexane-
l-hydroperoxide; 2,5-dimethylhexane-2,5 dihydroperoxide;
paramenthane hydroperoxide; 1,4-diisopropylbenzene
monohydroperoxide; p-t-butylisopropylbenzene
hydroperoxide; 2-(~-hydroperoxyisopropyl~-6-
isopropylnaphthalene; tetralin hydroperoxide and
combinations thereof. In the assay of urine for occult
blood, 1,4-diisopropylbenzene dihydroperoxide (DBD~) is
the preferred hydroperoxide because of the stability,
sensitivity, and nonvolatility of DBDH
The concentration of a hydroperoxide included
in the indicator reagent composition ranges from about 5
mM to about 100 mM~ and preferably from about 25 mM to
about 75 mM. The specific amount of a particular
hydroperoxide included in the indicator reagent
composition is dependent upon the physical and chemical
properties o~ the particular hydroperoxide, such as
volatility, stability and sensitivity towards a
predetermined analyte that exhibits peroxidative
activity.
In the assay for a predetermined analyte
capable of interacting with an oxidase enzyme, like
gluco~e or chole3~erol, the redox mediator includes a)
an oxidase enzyme that specifically interacts with the
predetermined analyte and b) a peroxidase enzyme. In
this assay, the predetermined analyte and the oxidase
enzyme first interact to generate hydrogen peroxide,
then the hydrogen peroxide and the peroxidase enzyme
interact to oxidi~e the indicator dye to cause a color
transition of the indicator rea~ent composition, wherein
MS-1654
~9~786~
- 36 -
the degree and intensity of the color transition are
correlated to the amount of predetermined analyte in the
test sample. As a result, a method of assaying for a
particular predetermined analyte can be designed by
utilizing a redox mediator including the appropriate
oxidase enzyme and peroxidase enzyme.
Accordingly, the oxidase enzyme included in
the indicator reagent composition is c:apable of
selectively interacting with the predetermined analyte
of interest as opposed to other constituents of the test
sample. For example, in the assay for glucose, glucose
oxidase is included as the oxidase enzyme; and in the
assay for cholesterol, cholesterol oxidase is included
as the oxidase enzyme. However, in addition to glucose
oxidase and cholesterol oxidase, other oxidase enzymes
that interact with a particular predetermined analyte to
generate oxidizing capability to oxidize the indicator
dye includey but are not limited to:
uricase,
aryl-alcohol oxidase,
L-gluconolactone oxidase,
galactose oxidase,
pyranose oxidase,
L-sorbase oxidase,
pyridoxin 4-oxidase,
alcohol oxidase,
L 2-hydroxyacid oxidase,
pyruvate oxidase,
oxalate oxidase,
glyoxylate oxidase,
dihydro~orotate oxidase,
lathosterol oxidase,
choline oxidase,
glycolate oxidase,
glycerol~3-phosphate oxidase,
xanthine oxidase,
MS-1654
8 ~ ~
- 37 -
sarcosine oxidase,
N-methylamino-acid oxidase,
N6-methyl-lysine oxidase,
6-hydroxy-L-nicotine oxidase,
6-hydroxy-D-nicotine oxidase,
nitroethane oxidase,
sulphite oxidase t
thiol oxidase,
cytochrome c oxidase,
Pseudomonas cytochrome oxidase,
ascorbate oxidase,
o-aminophenol oxidase, and
3-hydroxyanthranilate oxidase.
Such oxidase enzymes can be used in the assay for a
variety of predetermined analytes such as triglycerldes~
uric acid, glucose, cholesterol and galactose.
The concentration of the oxidase enzyme
included in the indicator reagent composition is
sufficient to interact with the entire amount of
predete~mined analyte in the test sample. Generally,
therefore, the amount of oxidase enzyme included in the
indicator reagent composi~ion is in the range of from
about sa units to about about 1000 units, and preferably
in the range of from about 50 units to about 250 units,
per milliliter (mL) of indicator rea~ent composition~
wherein one unit is defined as the amount of oxidase
enzyme to oxidize 1.0 ~mole (micromole) of substrat.e per
minute at the appropriate pH for the assay of interest
and at a temperature of about 30C. It ~hould be
understood that the amount of oxidase enzyme in the
indicator reagent composition can be greater than 1000
units per mL or less than 50 units per mL depending upon
the particular predetermined analyte of interest and the
expected concentration of that particular predetermined
analyte in the test sample.
MS-1654
2~67~6
- 38 -
Similarly, the amount of peroxidase enzyme in
the indicator reagent composition is sufficient to
interact with the entire amount of hydrogen peroxide
generated in the interaction between the oxidase enzyme
and the predetermined analyte. Generally, therefore,
the amount of peroxidase enzyme inclucled in the
indicator reagent composition is in the range of about
50 units to about 1000 units, and preferably, in the
range of from about 50 units to about 250 units, per mL
of indicator reagent composltion, wherein one unit is
defined as the amount to form 1 mg (milligram) of
purpurogallin from pyrogallol in 20 seconds at p~ 6.0 at
20CI It also should be understood that the amount of
peroxidase enzyme can be ~re~ter than 1000 units per mL
or less than 50 units per mL depending upon the
particular predetermined analyte of interest and the
expected concentration of that particular predetermined
analyte in the test sample.
Furthermore, in addition to the indicator dye
and the redox mediator, the indicator reagent
composition also includes a metal ion complex to impart
a~corbate resistance to the assayO In general, the
metal ion complex facilitates oxidation of the ascorbate
present in the test sample by the metal ion and thereby
eliminates the ascorbate interference. If the ascorbate
acid is not oxidized, the a~corbic can interact with the
colored, oxidized form of the indicator dye to provide
oxîdized ascorbic acid and the colorless, reduced form
of the indicator dye. Accordingly, an erroneously low
or a false negative assay for the predetermined analyte
results. Generally, the metal ions are included in the
indicator reagent composltion as a metal ion complex to
increase the solubility of the metal ion and to help
overcome the inherent peroxidative activity of metal
ions. However, a water-soluble salt of a metal ion also
can be included in the indicator reagent composition.
MS-1654
2~6~6
- 39 -
In accordance with an important feature of the
present invention, it is envisioned that essen~ially any
metal ion, when complexed, capable of oxidizing ascorbic
acid rapidly to eliminate ascorbate interference can be
included in the indicator reagent composition of the
present invention~ Accordingly, a metal ior useful in
the metal ion complex included in the indicator reagent
composition is selected from the group consisting of
ferric ion, cupric ion, mercuric ion, stannic ion~
nickel(II) ion, manganese(III) ion~ cadmium(II) ion,
zinc(II) ion, molybdenum(V) ion, chromium(IV) ion,
vanadium(III~ ion, ceric(IV) ion and combinations
thereof. In addition, other metal ions having a valence
state greater than (III~ also can be used as the metal
ion of the metal ion complex. To achieve the full
advantage of the present invention, the metal ion
present in the metal ion complex is the ferric ion.
As stated abovel the metal ion is complexed to
increase the water solubility of the metal ion and to
reduce the inherent peroxidative ac~ivity of the metal
ionq However, the identity of the complexing agent is
not particularly limited and, ~or example, can include a
polycarboxyalkylamine, like ethylenediaminetetraacetic
acid or nitrilotriacetic acid; a polycarboxylic acicl or
salt, like citric acid, oxalic acid, tartaric acid or
gluconic acid: a polyhydroxy compound, like sorbitol; a
lignosulfonate; a glucoheptonate;
bi~(dimethylglyoximato); salicylate complexes, li~e
bissalicylaldehydeethylenediiminato; dithioate
der~vatives; polyethyleneamine3, like triethyleneamine;
a 2,4-pentanedione derivative; a dipyridine derivative;
triethylenepyridine amine; a polypeptide containing
cysteine, glycine or histidine; a proline derivative; a
thiocrown ether, like 1,4,8,11,22,25-
octathiacycloocto~ane; a triphenylphosphine; orcombinations thereof.
MS-1654
2~7~
- 40
In particular, ferric ion complexes useful in
the indicator reagent composition includet but are not
limited to, the ferric ion polycarboxyalkylamine
chelates, such as the ferric ion chelates of N-(2-
hydroxyethyl)ethylenediaminetriacetic acid (Fe-HEDTA),
ethylenediaminetetraacetic acid (Fe-ED'$A),
cyclohexylenediaminetetraacetic acid (Fe-CDTA),
nitrilotriacetic acid (Fe-NTA~, iminodiacetic acid (Fe-
IMDA~, ethylenediaminedia~etic dipropionic acid (Fe-EDDP
both and ~ forms), hydroxyethyliminodiacetic acid (Fe-
HIMDA), diethylenetriaminepentaacetic acid (Fe-DTPA),
ethylenebis(oxyethylenenitrilo)tetracetic acid (Fe-
EGTA), N-(2-acetamido~iminodiacetic acid (Fe-ADA), or
combinations thereof. The ferric ion
polycarboxyalkylamine chelates are described more fully
in U.S. Patent No. 4,587,220, hereby incorporated by
reference. Other suitable ferric ion complexes include
ferric citrate, ferric gluconate, ferric glucoheptonate,
ferric bissalicylaldehydeethylenediiminato, and ferric
triethylenepyridine amine. The preferred ferric ion
complexe~ are Fe-HEDT~ and Fe-EDTA. To achieve the full
advantage of the present invention, the ferric ion
chelate Fe-EEDTA is included in the indicator reagent
composition of the present invention. It should be
understood however that the metal ion also can be
present in an uncomplexed form, such as a water-soluble
salt. For example, and as will be demonstrated more
fully hereinafter, mercuric nitrate has been utilized as
the metal ion in an uncomplexed form.
The metal ion complex is included in the
indicator reagent composition in an amount ranging from
about 0.5 mM to about 50 mM, and preferably in the range
of from about 1 mM to about 25 mM. When present in this
amount, the metal ion complex essentially eliminates
primary ascorbate interference in the assay of test
samples including up to about 200 mg/dL (milligrams per
MS-1654
2~67~66
- 41 -
deciliter) ascorbate~ In addition, it should be
understood that a suitable metal ion complex, like
Fe(III)-HEDTA, or a suitable metal salt, like mercuric
nitrate, can be commercially available, and therefore
incorporated directly into the indica~or reagent
composition. Alternatively, the metal ion complex can
be produced in situ during manufacture of the indicator
reagent composition, such as by independently
incorporating a metal ion salt, like ferric chloride
hexahydrate (FeC13 6~0), and an approximately equimolar
amount of a complexing agent, like N-(2-
hydroxyethyl)ethylenediaminetriacetic acid ~HEDTA), into
the indicator reagent composition to orm the Fe-HEDTA
ferric ion chelate.
When a composition including only an indicator
dye, a redox mediator and a metal ion complex is used in
a method to assay a test sample for a predetermined
analyte de~inite disadvantages become apparent. As
previously stated, the redox mediator is included in the
composition to interact with the predetermined analyte
for the oxidation of the indicator dye. The metal ion
csmplex is included in the composition to eliminate
prim~ry ascorbate interference from the assay. However,
ir. eliminating a~corbate interference by oxidizing the
ascorbate, the metal ion is reduced. This reduced form
of the metal ion can interact with the colored, oxidized
form of the indicator dye that results from the
predetermined analyte-redox mediator interaction. The
reduced form of the metal ion reduces the oxidized form
of the indicator dye to the colorless, reduced form of
the indicator dye, thereby diminishing the degree and
intensity of the color transition and providing an
erroneously low assay result for the predetermined
analyte.
MS-1654
- 42 -
Accordingly, the reduction of the oxidized
indicator dye by the reduced form of the metal ions
introduce~ a severe limitation on the sensitivity of a
dry phase test strip in the as~ay for a predetermined
analyte. As will be demonstrated more fully hereinafter
however, dry phase test strips incorporatlng an
indicator dye, a redox mediator, a metal ion complex and
a cooxidant selected from the group consisting of
bromate ion, chlorate ion~ perchlorate ion, chromate
ion, an organic oxidant like a peroxide, a hydroperoxide
or a N-halo oompound, and combinations thereof overcome
the erroneously low assay results previously observed in
an assay for a predetermined analyte.
Surprisingly and unexpectedly, it has been
found that including a suitable cooxidant in an
indicator reagent composition that further incl~ldes an
indicator dye, a redox mediator and a metal ion complex
sufficiently oxidizes the reduced form of the metal ion
such that the oxidiz~d indica~or dy~ is not reduced to
its colorless, reduced form by the reduced form of the
metal lon. In general, bromate ion, chlora~e ion or
perchlorate ion, chromate ion, an organic oxidant like a
peroxide, a hydroperoxide or a N-halo compound, or a
combination thereof, is a suitable cooxidant, and is
included in the i~dicator reagent composition of thle
present invention a~ a water soluble salt or water-
soluble compound.
Therefore, for example, the bromate ion i5
included in the indicator reagen~ composition as: a~ a
bromate salt having a counter cation suoh as potassium,
sodium, lithium, calcium, magnesium, ammonium, an
alkylammonium, a hydroxyalkylammonium, an
alkylphosphonium or a combination thereof, wherein the
alkyl or hydroxyalkyl group includes from one to about
six carbon atoms, in order to provide a sufficiently
water-~oluble bromate salt if an aqueous media is
MS-1654
~78~
- 43 -
desired, or b) a bromate salt having a counter cation
such as quaternary alkylammonium, cyanine~ pyridinium,
picolinium, guinalkinium, quinolinlum~ quaternary alkyl
phosphonium or combinations thereof, wherein the alkyl
group includes six or more carbon atoms in order to
provide a sufficiently water-insoluble bromate salt if a
nonaqueous media is desired. Similar counter cations of
chlorate, perchlorate and chromate salts also can be
used as the cooxidant, as long as the cation does not
adversely affect the assay for the predetermined
analyte. To achieve the full advantage of the present
invention, bromate ion is included in the indicator
reagent composition in the form of potassium broma~e.
The cooxidant also can be an organic oxidant,
like a peroxide, a hydroperoxide or a N-halo compound.
Examples of peroxides and hydroperoxides include, but
are not limited to, diisopropylbenzene hydroperoxide
(DBDH) r diisopropylbenzene monohydroperoxide,
phenylcyclohexane hydroperoxide, p (~~hydroperoxy-
isopropyl)benzoic acid, p-(bromoisopropyl)benæene
hydroperoxide and p~ hydroxy~
hydroperoxyisopropyl)benzeneO DBDH is the pref2rred
peroxide or hydroperoxide. A nonlimiting example of an
organic N-halo compound is a l-halobenzotriazole,
wherein the halo atom preferably is chloro.
In general~ the cooxidant is included in the
indicator reagent composition in a concentration ranging
from about 5 mM to abou~ 100 mM, and preferably in a
concentration ranging from about 20 mM to about 70 mM.
To achieve the full advantage of the present invention,
the cooxidant is bromate ion and is included in the
indicator reagent composition in a concentration ranging
from about 40 mM to about 60 mM. Within the above
concentration range, a sufficient amount of cooxidant is
present in the indicator reagen~ composition to oxidize
MS-1654
2~7866
- 44 -
the reduced form of the metal ion back to its oxidized
form.
An indicator reagent composition of the
present invention, including a cooxidant, allows ~or the
accuxate and sensitive assay of a predetermined
analyte. The metal ion complex, such as Fe~III)-HEDTA,
accomplishes the rapid two--electron oxidation of
ascorbic acid to eliminate ascorbic acid a5 an
interferent in the assay. The oxidatlon of ascorbio
acid is illustrated in the balanced reaction of Equation
10, wherein Fe(III)-HEDTA and Ee(II)-EIEDT~ ~re the
ferric and ferrous chelates of N-(2-
hydroxyethyl)ethylenediaminete~raacetic acid (HEDTA~,
respectively.
2 Fe(III)-HEDTA ~ Ascorbic acid
2 Fe(II)-HEDTA + 2H~ ~ Dehydroascorbate (9)
6 Fe(II)-HEDTA + BrO3~ ~ 6H+ -i~ 6 ~e(III)-HEDTA + Br~ -~- 3H20 (10)
3 Ascorbic acid ~ ~rO3~~ 3 Dehydroascorbate ~ 3r~ ~ 3H20 ( 11)
Surprisingly, the bromate ion, at a pH o from
about 5 to about 7, then oxidizes the reduced metal ion
of the metal ion complex from its lower valence state
(~e(II)-~EDTA) to its higher valence state (Fe~III)-
HEDTA), thereby preeluding an oxidation-reduction
interaction between the reduced metal ion and the
oxidized indicator dye. This interaction between
bromate ion and Fe(II)-HEDTA is illustrated in the
balanced reaction of Equation 10.
The stoichiometry of Equation 10 was
determined in a qualitative titration experimeQt by
adding known amounts Oe potassium bromate to a solution
including a known amount of ferrous ion buffered at pH
6.5. O-phenanthroline was used to detect remaining
Fe(~I) (eerrous) ion. The results of the titration
experiments are illustrated in T~BLE I. rn general, the
MS-1654
2 ~
- 45 -
Ee(II)-containing solution remained o-phenanthroline
reactive until the amount of potassium bromate added to
the solution reached an equivalent ratio of one. In
each qualitative titration, bromine (Br2) was not
detected by an analytical method capable of detectiny as
little as 10 uM (micromolar) ~romine. The reduction
product of bromate-ferrous ion interaction under the
above conditions therefore has been theorized to be
bromide ion (Br ). From TABLE I, it is seen that the
equivalent weight of potassium bromate therefore is one-
sixth of its molecular weight, showing a change of
bromine from the +5 oxidation state (BrO3~~ to the -1
oxida~ion state ~Br~). Accordingly, from T~BLE I and
Equation 10, to achieve the full advantage of the
present invention, the molar amount of bromate ion
included in the indica~or reagent composition i at
least one-sixth of the molar amount of the Fe(III)-HEDTA
included in the composition. The overall reaction
between Fe(III)-HEDTA, ascorbic acid and bromate ion is
illustrated in the balanced reaction o Equation 11.
2~
MS-1654
2 a ~
-- 46 --
Tl~lhE I
Oxidation of Fe(II)-~EDTA by KBrO3
Determination of Stoichiometry
Buffer: 0~5M citrate pH 6.5
S Initial Fe(II)~HEDTA concentration: 10 mM
Conc. Ratio Color upon
Experiment of Added Meq. KBrO to addition of
No. KBrO3, mM ~ o-phenanthroline
1 0 0 Red
2 0.33 0.2 Red
3 0.67 0O4 Red
4 1.0 0.6 Red
1.33 0.8 Red
6 1.67 1.0 NQ red
7 3~33 2.0 No red
Such results are unexpected because bromate
ion exhibits its oxidizing strength in low pH media~
whereas the assay for a predetermined analyte normally
is conducted in the essentially neutral p~ range of from
about 5 to about 7. ~urthermore, it has been found that
bromate ion does not oxidize the indicator dye to
provide a false positive or an erroneously high a~say
result; does not interfere with the interaction between
the predeter~ined analyte and the redox mediator;
exhibits a 3ufficiently fast reaction rate with the
reduced form of the metal ion; operate~ at the neutral
pH range nece~sary for enzymatic interactions; and is
reduced to the innocuous bromide ion ~ Br~ ) as opposed to
the highly-colored bromine molecule ~Br2~ tha~
interferes with the colorimetric response of the
in~icator reagen~ composition.
In accordance with another important feature
of the present invention it has been found that the
concentration of the metal ion complex and the
MS-1654
2~78~g
- 47 -
concentration of the cooxidant in the indicator reagent
compositions affects the rate of ascorbic acid
oxidation. For example, the rate of ascorbic acid
oxidation o an aqueous solution that was 0.1 mM
~millimolar~ in ascorbic acid, 25 ~M (micromolar) in
Fe~III)-HEDTA and a variable amount of potassium
bromate, and having a buffer p~ of 6.5, was determined
by following the decrease in absorbance at 265 nm
(nanometers).
In particular, FIG. l inclucles a series of
plots of absorbance at 2~5 nm (A265) vs. time for
solutions at pH 6.5 that were 0.1 mM in ascorbic acid,
25 ~M in FetIII)-HEDTA, and were either 0, 0.5, l, 5 or
10 mM in potassium bromate. ~ decrease in A2~5 shows
that ascorbic acid is oxidized. Therefore, FIG. l shows
that in the absence of potassium bromate (O mM KBrO3),
the A265 slowly, but measurably, decreases due to the
pre~ence of the Fe(III3-~EDTA. As the concentration of
potassium bromate increased over the range of 0.5 mM to
10 mM the rate of change in ~265 increases. FI~. 2
shows that platting the first order rate constant (k,
sec~l) for the oxidation step vs. the potassium bromate
concentr~tion provided a straight line that intersects
the y-axis at 0.01 sec 1. Because the rate constant for
the reaction is proportional to the potassium bromate
concentration under these conditions, the reoxidati.on of
Fe(II) to Fe~III) apparently is the slow step in this
ascorbate oxidation mechanism. FIG. 3 shows that ~hen
the potassium bromate level was fixed at 0.5 mM and the
Fe(III)-HEDTA concentration was increased over the range
of 0 to 50 ~M, the rate of ascorbic acid oxidation was a
function of the Fe(III)-HEDTA concentration.
Accordingly, as the Fe(III)-HEDTA concentration is
increased, the rate of ascorbic acid oxidation i5
increased.
Therefore, and in accordance with an important
MS-1654
2~786~
- 48 -
feature of the present invention, bromate ion, chlorate
ion or perchlorate ion, chromate ion, an organic oxidant
like a peroxide, a hydroperoxide or a N-halo compound,
is included in the indicator reagent composition of the
present invention as a cooxidant to complete the
oxidation-reduction cycle of the metal ion in the metal
ion complex. The metal ion complex~ like a ferric ion
chelate, catalytically oxidizes the ascorbate, and the
fexric ion then is regenerated by the coo~idant~
Ac~ordingly, the cooxidant increases the sensitivity of
an assay for a predetermined analyte. The improved
indicator reagent composition also demonstrates the
advantages of low toxicity, stability, a minimum of side
reactions and compatibility between ingredients of the
indicator xeagent composition~ As will be demonstrated
more fully hereinafter, it is both surprising and
unexpected for an indicator reagent composition,
including bromate ion, chlorate ion or perchlorate ion,
chromate ion, an organic oxidant like a peroxide, a
hydroperoxide or a N-halo compound, to eliminate the
secondary interfering affects of the reduced metal ion
of the metal ion complex at the essentially neutral p~
wherein a test sample is assayed for a predetermined
analyte.
In addition to the essential ingredients
described above, the indicator reagent composition can
include a su~ficient amount of a suitable buffer, such
that the indicator dye changes color as a result of an
interaction between the predetermined analyte and the
redox mediator, and not as a result of a change in p~.
Test samples often have a pH outside the desired p~
range for the assay of interest and therefore a buffer
is added to the test composition. Accordingly, it has
been demonstrated that any of various known types of
buffers can be included in the indicator reagent
composition of the present invention. The buffer is
MS-1654
2 ~
- 49 -
especially irnportant in a commercially-acceptable dry
phase test strip that resists the affects of urine pH
and urine specific gravity. The function of the buffer
is to maintain the indicator reagent composition at a
proper p~ to stabilize the indicator reagent composition
and produce the desired color transiti~n in the
indicator dye during the assay.
A buffer is included in the indicator reagent
composition of the present invention usually in a
concentration range of between 0 mM to about 600 mM, and
preferably between about 50 mM to about 400 mMr although
in particular situations the concentration of the buffer
can be above or below this range. To achieve the full
advantage o~ the present invention, the optional buffer
is present in a concentration ranging from about 150 mM
to about 300 mM. It has heen found that for optimum
assay results, the pH of the indicator reagent
composition generally should be maintained at a slightly
acidic to a neutral p~ valu~. Therefore, a pH of from
about 5 to about 7) and preferably of from about 6 to
about 7, provides a more spectacular and a more easily
differentiable color transition in the as~ay for a
predetermined analyte. Surprisingly, it has been found
that bromate ion, chlorate ion, perchlorate ion,
chromate ion, an organic oxidant like a peroxide, a
hydroperoxide or a N-halo compound, effectively oxidizes
the reduced metal ion at this sli~htly acidic tQ neutral
p~ range such that the full color transition is detected
to provide optimum assay results, absent primary and
secondary interference~ attributed to ascorbate and ~o
the reduced form of the metal ion respectively.
For example, the prior art teaches that when a
ferric ion complex, like the ferric ion chelate of N-(2-
hydroxyethyl)ethylenediaminetriacetic acid
(Fe(III)-H~DTA), is included in the indicator reagent
composition to provide the desired ascorbate resistance,
MS-1654
2~7~
- 50 -
the indicator reagent composition is buffered above a pH
of 6.5, such as at a pH range of 6.7 to 7~0. Most
preferably, the pH is buffered at 6.8 to 6.9. This p~
range provides the best balance of sensitivity,
stability and ascorbate resistance when assaying urine
samples exhibiting highly variable pH values and
specific gravity. Surprisingly, bromate ion, chlorate
ion, perchlorate ion, chroma~e ion, an organic oxidant
like a peroxide, a hydroperoxide or a N halo compound,
or a combination thereof~ sufficiently oxidized the
ferrous ion resulting from the ascorbate oxidation to
ferric ion at this essentially neutral pH.
Therefore, optionally; well-knQwn buffers such
as acetate, phthalate; borate; trichloracetate;
sulfosalicylate; phosphate; tartarate; citrate,
succinate; maleic a id; 2,2-bisthydroxymethyl)-2,2'2"-
nitrilotriethanol, 3,3-dimethylglutaric acid; 3-N-
morpholinopropanesulfonic acid (MOPS); malonic acid;
1,3-b.is[tris(hydroxymethyl)methylamino]propane (Bis-
tri~); tris(hydroxymethyl~aminomethane (Tris);tris(hydroxymethyl)aminomethane-maleic acid (Tris-
maleate); tris(hydroxymethyl)aminomethane-malonic acid
(Tris-malonate); 3-N-(trishydroxymethyl)methylamino-2-
hydroxypropanesulfonic acid (TAPSO); 2-
([tris(hydroxymethyl1methyl]amino)ethanesulfonic acid(TES); 1,4-piperazinebis(ethanesulfonic acid) (PIPES);
4-morpholinoethane~ulfonic acid (MES); N-2-
hydroxyethylpipera~ine-N'-2-ethanesulfonic acid ~EPES);
and other suitable buffers as are well known in the art,
or combinations thereof, can be included as the optional
buffer in the indicator reagent composition of the
present invention.
The indicator rea~ent composition of the
present invention, including an indicator dye, a redox
mediator, a metal ion complex and a cooxidant selected
from the group consisting of bromate ion, chlorate ion~
MS-1654
2~7~6~
- 51 -
perchlorate ion, chromate ion, an organic oxidant like a
peroxide, a hydroperoxide or a N-halo compound, and
combinations thereof, is utilized in an improved method
to determine the presence or the concentration of a
predetermined analyte in a liquid test sample. It has
been demonstrated that the indica~or reagent composition
is stable previous to contact with a liquid test sample~
~nd then interacts with a predetermined analyte in the
test sample to produce a differentiable and measurable
color transition, either visually or by instrument~
E'urthermore, in addition to the essential ingredients
described above, the indicator reagent composition of
the present invention can include a sufficient amount of
optional ingredients, like a buffer, such that the
indicator dye changes color upon contac~ and interaction
with the oxygen that is catalytically relea~ed in the
interaction between the predetermined analyte and the
redox mediato~. Accordingly, the color change, free
from interfering affect~ attributed to ascorbate and to
the reduced form of the metal ion, accurately
e~tahlishes the pre~ence or concentration of the
predetermined analyte in the test sample.
In addition to the e~sential ingredients, the
lndicator r~agent composition al50 can include other
optional ingredients, in addition to the buffer, that do
not materially alter the nature and the function of the
essential ingredients, and that do not interfere with
the a~say for a predetermined analyte. ~or example, the
indicator reagent composition optionally can include a
compound to improve the wetting of the test pad of the
test device by the test sample and to stabilize the
oxidized indicator dye. This compound usually is an
anionic surfactant or a nonionic surfactant. An anionic
surfactant, such a~ a long carbon chain sulfate or
sulfonate, like sodium dodecyl sulfate, dioctyl sodium
sulfosuccinate and sodium dodecylbenzene sulphonate, is
~S~
2 ~ 6
~he preferred surfactant. Nonionic surfactants, such as
an octoxynol, a nonoxynol or an ethoxylated fatty
alcohol, also can be included in the indicator reagent
composition o~ the present invention. The surfactant is
included in the indicator reagent composition in a
con~entration of from 0 mM to about 200 mM, and
preferably in a concentration of from about 50 mM to
about 150 mM.
The indicator reagent composition also can
include a polymeric material that improves the stability
and uniformity of the color transition of the test
device. Suitable polymeric materials include, but are
not limited to, polyvinylpyrrolidone, polyvinyl alcohol,
gum arabic, gelatin, algin, carrageenan, casein,
albumin, methyl cellulose and similar natural and
synthetic polymeric materials. The preferred polymeric
material is a polyvinylpyrrolidonei such as PVP K-30, a
polyvinylpyrrolidone of molecular weight 40,000 and
available commercially rom GAF Corp., New York, NY~
The polymeric material generally i5 included in the
indicator reagent composition in amounts from 0~ to
about 5%, and preferably from about 1% to about 4~, by
tvtal weight of the indicator reagent composition.
In addi~ion, to improve the color resolution
and differentiation of the color ~ransition in a
chromogenic a~say for a predetermined analyte, inert
background dyes can be include~ in the indicator reagent
composition. Suitable background dyes include, but are
not limited to, ethyl orange t4-(4-
diethylaminophenylazo)benzenesulfonic acid); Orange G(4-[2-hydroxy-(7,9 sodium disulfonate)-l-
naphthylazo)benzene); disperse orange ll, 13 or 25;
calcomine orange; methyl orange; and orange (II)(4-~2-
hydroxy-l-naphthylazo)benzenesulfonic acid); or
combinations thereof. A background dye i9 included in
the indicator reagent composition of the present
MS-1654
2~6786~
- 53 -
invention in a concentration ranging from 0 mM to about
2 mM, and preferably ranging from about 0.1 mM to about
1.2 mM.
The carrier vehicle for the ingredients
S included in the indicator reagent composition includes
water. However, because of the limited water solubility
of particular ingredients included in the indicator
reagent composition, organic solvents such as methanol,
ethanol, isopropyl alcohol/ acetone, dimethylf3rmamide,
1-methoxy-2-propanol, dimethylsulfoxide, acetonitrile,
ethyl ace~ate and similar solvents Call be included in
the carrier vehicle. The selection of a suitable
organic solvent or solvents, in addition to water, to
include in the carrier vehicle of the indicator reagent
composition is within the capability of those skilled in
the art of designing diagnostic assays.
The amount of organic solvent present in the
indicator reagent composition generally is in the range
of from 0~ to about 90~, and preferably from abou~ 10%
to about 70%, by weight of the carrier vehicle. A
carri~r vehicle comprising water and an organic solvent,
like ethanol or acetonitrile, is especially preferred
because a carrier matrix impregnated with the indicator
reagent composition can be dried within a few to several
minutes.
A~ previously described, the indicator reagent
composition undergoes a color transition upon contact
with a te~t ~ample to demonstra~e the presence of a
predetermined analyte. ~urthermore, the intensity and
degree of the color transition are u~ed to determine the
quantitative concentration of a predetermined analyte in
the test sample by comparing or correlating the color
produced by the test sample to colors produced by
solution3 having a known concentration of the
predetermined analyte. In accordance with an important
feature of the present invention, it has been
MS-1654
2~78~
demonstrated that an indicator reagent composition of
the present invention provides a sufficiently resolved
and differentiated color transition such that the amount
of a predetermined analyte in a test sample can be
measured and accurately determined without the use of
color-measuring instruments, such as spectrophotometers
or colorimeters. However, if desired, such color-
measuring instruments can be used to m~easure the
difference in color degree and intensity between the
test sample and a solution having a known concentration
of the predetermined analyte.
Accordingly, an assay for a predetermined
analyte that utilizes an indicator reagent composition
of the present invention improves the accuracy and
reliability of the assay and also increases physician
confidence in the assay~ Additionally, because of the
number of assays for a predetermined analyte being
performed at home by the untrained patient, as opposed
to trained physicians or technicians in the laboratory,
it is imperative to provide accurate and re~iable
quantitative assay methods for a predetermined analyte,
like glucose, in a te~t sample, like urine.
To demonstrate the new and unexpected results
achieved by the method of the present invention, an
indicator reagent compo~ition, including an indicator
dye, a redox mediator, a metal ion complex and a
cooxidant ~elected from the group consisting of ~romate
ion, chlorate ion, perchlorate ion, chromate ion, an
organic oxidant like a peroxide, a hydroperoxide or a N-
halo compound, and combinations thereof, was used in dryphase te~t strip assay for a predetermined analyte. The
dry phase test strip assay utilizing the indicator
reagent composition of the present invention is
performed ln accordance with methods well known in the
art. In general, the assay for a predetermined analyte
is performed by contacting the whole blood, blood serum,
MS-1654
`
2~6786~
- 55 -
blood plasma, urine or other test sample with an analyte
detection device that includes the indicator reagent
composition. The analyte detection device can be dipped
- into the test sample, or the test sample can be applied
to the analyte detection device dropwise. The resulting
change in color of the analyte dPtection device
demonstrates the presence of the predetermined analyte;
and, if so designed, the resulting color transition can
be compared to a standardized color ehart to provide a
quantitative measurement of the concentration of the
predetermined analyte in the test sample.
Typically, the analyte detection device i~ a
reagent impregnated te4t strip~ designed either as a
single pad test strip ~to assay only for a single
analyte) or as a multiple pad test strip (to assay for
several analytes simultaneously). For either type of
reagent impregnated test strip, the test strip typically
includes a support strip, or handle, normally
constructed from a hydrophobic plastic, and a reagent
test pad~ comprising a bibulous or a nonbibulous carrier
matrix incorporating the indicator reagent
composition. In general, the carrier matrix is an
absorbent material that allows the test sample to move,
in response to capillary forces, through the carrier
matrix to contact the indicator reagent composition and
produce a detectable or measurable color transition.
The carrier matrix can be any substance
capable of incorporating the chemical rea~ents required
to perform the assay of interest, as long as the carrier
matrix is substantially inert with respect to the
chemical reagents, and is porous or ab~orbent relative
to the liquid test sample. The expression "carrier
matrix" refers to either bibulous or nonbibulous
matrices that are insoluble in water and other
physiological fluids and maintain their structural
integrity when exposed to water and other physiological
MS-1654
2~7gfi~
- 56 -
fluids. Suitable bibulous matrices include filter
paper, sponge materials, cellulose, wood, woven and
nonwoven fabrics and the like. Nonbibulous matrices
include glass fiber, polymeric films, and preformed or
microporous membranes. Other suitable carrier matrice~
include hydrophilic inorganic powders, such as silica
gel, alumina, diatomaceous earth and the like;
argillaceous substances; cloth; hydrophilic natural
polymeric materials, particularly cellulosic material,
like cellulosic beads, and especially fiber-containing
papers such as filter paper or chromatographic paper;
synthetic or modified naturally-occurin~ polymers, such
as cellulose acetate, polyvinyl chloride,
polyacrylamide, polyacrylates, polyurethanes,
crosslinked dextran, agarose, and other such crosslinked
and noncrosslinked water-insoluble hydrophilic
polymers. ~ydrophobic and nonabsorptive substances are
not suitable for use as the carrier matrix of the
present inven~ion. The carrier matrix can be of
different chemical compositions or a mixture of chemical
compositions. The matrix also can vary in regards to
smoothness and roughne~s combined with hardness and
softness. The carrier matrix is most advantageously
constructed from bibulous filter paper or nonbibulous
polymeric films. ~owever, in every instance, the
carrier matrix includes a hydrophilic or absorptive
material. The handle usually is formed from a
hydrophobic material such as cellulose acetate~
polyethylene terephthalate, polycarbonate or
polystyrene.
If the test strip is designed to assay for a
predetermined analyte in a test sample, the carrier
matrix can be any bibulous or nonbibulous material that
allows permeation by the test sample to saturate the
test pad of the test strip that incorporates the
indicator reagent composition. To achieve the full
MS-1654
X0~7~
- 57 -
advantage o~ the present invention, in the assay for a
predetermined analyte in a test sample, the carrier
matrix is a hydrophilic, bibulous matrix, including
cellulosic materials, such as paper, and preferably
filter paper. Filter paper possesses all o the
qualities required of a bibulous matrix of the present
invention, plus the advantages of abundant supply,
favorable economics, and a variety of suitable grades~
Filter paper has been found to be extremely satisfactory
for use as a matrix material for suspending and
positioning both the essential ingredients and any
optional ingredients included in the indicator reagent
composi~ion.
To achieve the full advantage of the present
invention, the indicator reagent composition is
incorporated into a suitable carrier matrix and utilized
in a dry phase test strip for the assay of a
predetermined analyte in a test sample. The method of
the present invention affords an economical, accurate
and reliable assay, performable at home or in the
laboratory, for the presence or concentration of a
predetermined analyte in a test sample. In addition,
the method of the present invention allows the
detection, differe~tiation and measurement of a low
concentration of a predetermined analyte in the test
sample therefore making the assay more useful
clini~ally.
In accordance with the method of the present
invention, to perform a dry phase test s~rip assay for a
predetermined analyte capable of interacting with an
oxi~ase enzyme, like glucose, an aqueous solution,
including from about 5Q units to about 1000 units of the
appropriate oxidase enzyme; from about 50 units to about
1000 units of a peroxidase enzyme; from about 5 mM to
about 60 mM of an indicator dye; from 0.5 mM to about 50
mM of a metal ion complex; from about 5 mM to about 100
MS-1654
2~866
- 58 -
mM of a cooxidant selected from the group consisting of
bromate ion, chlorate ion, perchlorate ion, chromate
ion, an organic oxidant like a peroxide, a hydroperoxide
or a N-halo compound, and combinations thereof; 0 mM to
S about 600 mM of a buffer such as a citrate buffer; from
O mM to about 200 mM of a surfactant; from 0~ to about
5% of a polymeric material; and any other desired
optional ingredients, like background dyes or solvents,
first is prepared. This aqueous solution then is
adjusted to a pH of Erom about 5 to about 7 with a
suita~le organic acid or mineral acid, such as lN
hydrochloric acid. ~ bibulous matrix, such as filter
paper, then is saturated with the aqueous solution by
immersing or by sprayin~ the aqueous solution onto
sheets or precut strips of the filter paper.
Then, the aqueous solvent is removed by drying
the saturated filter paper in an air oven at a
temperature of from about 40C to about lOO~C for about
2G minutes. After oven drying, the reagent-impregnated
filter paper is cut to an appropriate size, such as a
pad having dimensions from about 0.25 cm by about 0.5 cm
to about 0.5 cm by about 1.0 cm.
Similarly, to perform a dry phase test strip
assay for a predetermined analyte that exhibits
peroxidase activity, like occult blood, the redox
mediator is changed from an oxidase enz~me and
peroxidase to a hydroperoxide. Therefore, an aqueous
solution, including from about 5 mM to about 60 mM of an
indicator dye; from about 0.5 mM to about 50 mM of a
metal ion complex; from about 5 mM to about 100 mM of a
hydroperoxide; from about 5 ~M to about 100 mM of a
cooxidant; 0 mM to about 600 mM of a buffer such as
sodium citrate; from 0% to about 5% of a polymeric
material; from 0 mM to about 200 mM of a surfactant; and
any other desired optlonal ingredient~, like background
dyes or solvents, first i~ prepared. Then, after the pH
MS-1654
2~8~
is adjusted to within the range of about 5 to about 7,
the aqueous solution is incorporated into a carrier
matrix, and the carrier matrix is dried and finally cut
to an appropriate size as discussed above~
In either case, the dried and cut, reagent-
impregnated filter paper then is secured to an opaque or
transparent hydrophobic plastic handle with double-sided
adhesive tape. The resulting test strip then is dipped
into a test sample, such as a fresh, uncentrifuged urine
sample, for a sufficient time to saturate the tes~ pad
with the sample. After waiting a predetermined time,
such a~ from about 15 secs. to about 60 secs., the test
strip is examined, either visually or by instrument, for
a response. The color tra~sition, if any, of the test
pad reveals the presence or concentration of a
predetermined analyte in the urine sample.
It should be understood that i~ is well wi~hin
the experimental techniques of those skilled in the art
of preparing te~t device~ to determine the proper
halance between size of reagent pad, the strength of
reagent impregnating ~olutions, the amount of test
sample, and the method of introducing the test sample to
the te~t strip, such as by pipetting rather than
dipping, in order to design a quantitative assay for a
predetermined analyte utilizing the method and
composition the present invention.
in many cases, simple visual observation of
the test strip provide~ the desired information. I~
more accurate information is required, a color chart
bearing color spots corresponding to various known
conc2ntrations of the predetermined analyte can be
prepared for th~ particular indicator reagent
composition used in the te~t strip. The resulting color
of the test strip after contact with the test sample
then can be compared with the color spots on the chart
to determine the concentration of predetermined analyte
MS-1654
2~8~
- 60 -
in the test sample. If a still more accurate
determination is required, a spectrophotometer or
colorimeter can be used to more precisely determine the
degree of color transition. In addition, the dry phase
test strip assay can be made quantitative by employing
spectrophotometric or colorimetric techniques, as
opposed to visual techniques, in order to more reliably
and more accurately measure the degree of color
transition, and therefore more accurately measure the
concentration of the predetermined analyte in the test
sample, especially at lower concentrations, such as
below one mg/dL.
Therefore, in accordance with an important
feature of the present invention, it has been
demonstrated that by incorporatin~ an indicator reagent
composition of the present invention into a suitable
carrier matrix, the presence or concentration of a
predetermined analyte in a test sample can be achieved
by using a dry phase test strip. As previously
discussed, a dry phase test strip used for the assay o~
a predetermined analyte in a test sample generally
includes a carrier matrix comprising any absorbent
matrix that i~ amenable to treatment with and
incorporation of the indicator reagent composition; that
permits the blood, urine or other test sample to
permeate the carrier matrix rapidly enough to obtain a
reliable assay relatively quickly; and that does not
contaminate the blood, urine or other test sample either
by test sample extraction of components comprising the
carrier matrix or by appreciably altering the test
sample in a way to make the subsequen~ assay
inconclusive, inaccurate and doubtful.
In accordance with one embodiment of the
present invention, the following dry phase test strips
were prepared to perform a dry phase assay for a
glucose. Glucose is capable of interacting with glucose
MS-1~54
2~6~6~
- 61 -
oxidase to generate hydrogen peroxide. Therefore the
following aqueous composition of Example I was
prepared. Then, the composition of Example I was
applied to a strip or sheet of a carrier matrix, like a
film of porous polyurethane, with a Meyer rod.
EXAMPLES
INDICATOR REAGENT COMPOSITION
Example I Example II
Ingredlent Concentration Concentration
10 Tetramethylbenzidine (TMB)35 mM 35 mM
(Indicator Dye)
Sodium Citrate (Buffer)250 mM 250 mM
Ferric chloride (Metal ion) 5 ~M
N-(2-hydroxyethyI)ethylene-
diaminetetraacetic acid
(Complexing agent for the
metal ~on) 5 mM --
Peroxidase 1000 units/mL lOOO units/mL
Potassium bromate 20 mM
20 Glucose Oxidase lOOO units/mL lOOO units/m~
Sodium Dodecyl Sulfate
(Surfactant) 28 mM 28 mM
Hydrochloric Acid (1N)to ad~ust pH toto adJust pH to
about 6.0 about 6.o
The layer of indicator reagent composition on
the polyurethane matrix then was dried in an oven having
a temperature rangin~ from about 45C to about 60C for
about 10 minutes. The polyurethane matrix incorporating
the dried indicator reagent composition then was cut
into a pad having dimensions of about 0.5 cm by about
0.5 cm to provide a test pad comprising a carrier matrix
in~orporating an indicator reagent composition of the
present invention. The test pad then was secured to a
MS-1654
~7~6
- 62 -
hydrophobic plastic handle with double-sided adhesive to
provide a dry phase test strip of the present invention.
In addition, it should be understood that the
indicator dye can be incorporated directly into the
polyurethane matrix during the manufacture of the
polyurethane matrix. Often the indicator dye has a low
water solubility thereby making it difficult to
solubilize the indicator dye in the aqueous solution.
~owever, because the indicator dye often demonstrates
excellent solubility in organic solvents, the indicator
dye is solubilized in the organic solvent used in the
manufacture of the polyurethane matrix.
To demonstrate the new and unexpected results
achieved by the method of the present invention, dry
phase test strips incorporating an indicator reagent
composition of the present invention (Example I) were
compared to dry phase test strips incorporating an
indicator reagent composition (Example II) including the
ingredients of Example I, except the bromate ion, the
ferric chloride and the N-(2 hydroxyethyl)-
ethylenediaminetetraacetic acid were omitted. The test
strips incorporating the composition of Example II were
used as a control to demonstrate the improved assays
provided by an indicator reagent composition of the
present invention, i.e., Example I.
Individual dry phase test strips incorporating
either the ~omposition of Example I or the composition
of Example II were compared in the assay of standardized
solutions including 100 mg/dL glucose and from 0 mg/dL
to 200 mg/dL ascorbic acidO The test strips were dipped
into a standardized solution irlc~uding the glucose and
ascorbic acid, then approx.imately one minute after
contacting the standardized solution, the reflectance of
the test pad of the test strip was measured at 660 nm
(nanometers) on an Advanced Research Rap.id Scanner
reflectance spectrometer, of the Diagnostics Division of
MS-1654
2~67~66
- 63 -
Miles Inc., Elkhart, IN. The reflectance measuremen~
represents the reactivity of a particular dry phase test
strip towards a solution including a standardized amount
of glucose.
TABLE II summarizes the reactivity of dry
phase test strips including an indicator reagent
composition absent bromate ion and a metal ion complex
(Example II), and test strips including a composltion of
the present invention (Example I). In general, from
TABLE II, assays performed with test strips
incorporating an indicator reagent composition of
Example I show a substantially greater resistance to
ascorbic acid interference than assays performed with
test strips incorporating the composition of Example II.
TABI,E II
a Metal Ion Com~lex and Bromate Ion
~est Glucose Ascorbate
Sam~le Concentration (mq/dL~ Concentration (mg/dL)
A 100 o
B lO0 50
C 100 100
D lO0 200
Test . Indicator Reaqe t Com~osition
25 Sampl~ EX. l EX. 2
A lO0l) lO01)
B >30 30
C >30 0
D >30 0
1 ) Apparent glucose concentration in the standardized
test sample, in mg/dL.
MS-1654
2~7~6~
- 64 -
The test strips incorporating an indicator
reagent composition of the present invention (Example I)
were evaluated for ascorbate resistance by comparison to
control strips incorporating the indicator reagent
composition of Example II. In each assay, the strip was
dipped into standardized glucose solut.ion including 0,
30 or 100 mg/dL of glucose, or including 100 mg/dL
glucose and either 0, 50, 100 or 200 mg/dL of ascorbic
acid. The standardized solutions including 0, 30 or 100
mg/dL glucose, and no ascorbic acidr provided
standardized responses to glucose. The responses of
assays performed on solutions include 100 mg/dL glucose
and varying amounts of ascorbic acid were compared to
these standardized responses.
In general, the data presented .in TABLE IX
show that a test strip incorporating a composition of
the present invention (Example I) demonstrate a
detectable color transition with an apparent glucose
concentration of greater than 30 mg/dL, even in the
presence of 200 mg/dL ascorbic acidO However, a test
strip including a composition absent a metal ion complex
and bromate ion (Example II) shows an apparent ~lucose
concen~ration of 0 mg/dL in the presence of 100 mg/dL
ascorbic acid.
In particular, a test sample including no
ascorbate as an interferent (Te~t Sample A) is
accurately assayed or glucose (100 mg/dL) by the
composition of Example I or the composition of Example
II. However, when ascorbate is included in the test
sample, the composition of Example I demonstrated a
sufficient response to show that greater than 30 mg/dL
of glucose is present in the test sample regardless of
the amount of interfering ascorbate tha~ is present.
However, for test strips incorporating the composition
of Example II, if 100 mg/dL or 200 mg/dL of ascorbic
acid is included in the test sample (Test Samples C and
MS-1654
2~786~
- 65 -
D), the test strip did not undergo a color transition.
In contrast, a test strip incorporating a composition of
the present invention, still demonstrated a response of
greater than 30 mg/dL glucose when 200 mg/dL ascorbic
acid was present in the test sample (Test Sample D). A
composition of the present invention similarly provided
improved assay results when 50 mg/dL ascorbic acid is
present in the test sample.
To further demonstrate the usefulness of the
present invention, it has been found that bromate ion
and Fe(IIIl-HEDTA also effectively eliminate ascorbate
interference in an assay for cholesterol. TABLE III
summarizes the results of five wet phase cholesterol
assays. The assays were performed to determine the
effectiveness of a composition including cholesterol
oxidase, peroxidase, tetramethylbenzidine (TMB) dye, a
metal ion complex and a cooxidant in reducing or
eliminating interferences due to ascorbic acid in an
assay for cholesterol.
MS-1654
2~67~
- 66 -
TABLE III
. _
Im~roved_Ascorbate Resistance Ln the
Assa. '~o~ Ch~:es~ero
Test Choleste~l
5 Sample Waterl) Buffer2) Oxidase Peroxidase4) TMB5)
A0.86 0.10 10 10 10
~0.85 0.10 lo lo lo
C0.84 0.10 10 10 10
D0.83 0.10 10 10 10
E0.82 0.10 10 10 10
Test Asco~ic ColorlO)
Acid Fe(III)-HEDTA7) K8rO38) Cholester_19) _rmation
A - -- -- 10 Yes
B 10 -- -- 10 No
C 10 10 -- 10 No
D 10 10 10 10 No
E 10 10 20 10 Yes
1) in milliliters (mL), each test sample had a total
volume of 1 mL:
0 2~ in mL, the buffer is lM 2-(N-
morpholino)ethanesulfonic acid (MES), pH-6.5.
3) in microliters (~L), of 100 mg/mL of cholesterol
oxidase in water (1330 units/mL), available from
GDS Technology, Inc., Elkhart, IN.;
4) in ~L, of 100 mg/mL of peroxidase in water (103
units/mg);
5) in ~L, of a 100 mM solution of
tetramethylbenzidine (TM~) in l-methoxy-2-
propanol, a~ the indicator dye;
6) in ~L, of a 0.56 M solution of ascorbic acid (10%
ascorbic acid by weight), test samples ~ through E
each include 5.6 mM (millimolar) ascorbic acid;
7) in ~L, of a 100 mM solution of Fe-HEDTA, te~t
sample C through E each include 1.0 mM
Fe(III)-HEDTA;
~5-1654
. .
2 ~
- 67 -
8) in ~L, of a 0.2 M aqueous solution of potassium
bromate, test sample D includes 2.0 mM KBrO3 and
test sample E includes 4.0 mM KBrO3;
9) in ~L, of a serum lncluding 333 mg/dL
(milligram/deciliter) cholesterol; and
10) test sample was examined for the formation of a
blue color
The tests illustrated in TABLE III were
performed in a 1~ mm (millimeter) by 75 mm glass test
tube. For test sample A, the cholesterol oxidase, the
peroxidase, the TMB and the MES buffer solutions first
were added to the test tube. Then, the reaction was
initiated by adding the cholesterol-containing serum to
the test tube. The total volume in the test tube for
test sample A, and for test samples B through E, was
1.00 mL. After about from 10 to 15 seconds, the
reaction solution became blue in color, indicating the
presence of cholesterol in the test sample. Test sample
A was the control sample that included no ascorbic acid
as an interferent, and accordingly the indicator dye
underwent a full color transition in response to the
amount of cholesterol present in test sample A.
Test sample B was subjected to an identical
assay, except that te~t sample B also was 5.6 mM in
ascorbic acid. The ascorbic acid interfered
su~ficiently such that no color transition of the
reaction solution to b~ue was observed. Test sample C
was subjected to an identical assay as test sample B
except that test sample C also was 1.0 mM in
Fe(III)-HEDTA. Again no color transition to blue was
observed. Although the Fe(III)-HEDTA eliminated the
ascorbate interference, the generation of ferrous ions
from the ~e(III)-HEDTA/ascorbate interaction provided a
secondary interference in that the ferrous ions
interacted with the oxidized, colored form of TMB to
regenerate ferric ions and the reduced, colorless form
MS-1654
2067~6~
- 68 -
of TMB. Accordingly, the assay was a false negative
assay for cholesterol.
Test sample D was subjected to an identical
assay as test sample C, except that test sample D al50
was 2 mM in potassium bromate. Again no color
transition to blue was observed. However, in test
sample E, identical to test sample D except for being 4
mM in potassium bromate, a color change to blue was
observed. This color change was essentially identical
in degree and intensity to the color change of test
sample A, thereby showing that the interfering affects
of the ascorbic acid have been overcome by including a
metal ion complex and a sufficient amount of a suitable
cooxidant in the indicator reagent composition.
To demonstrate that other metal complexes and
other cooxidants also can be used in an indicator
reagent composition of the present invention to reduce
or eliminate the interfering affects of ascorbic acid in
an assay for a predetermined analyte, se~eral dry phase
test strips including different metal ion complexes and
different cooxidants were prepared and used to assay for
glucose. The test strips utilized fil~er paper as the
carrier matrix, and incorporated an indicator reagent
composition comprising tetramethylbenzidine dye (TMB),
glucose oxidase and peroxidase into the carrier
matrix. The indicator reagent composition also included
a buffer and either a cooxidant or a metal ion complex
or a combination of a cooxidant and a metal ion
complex. The test strips were used to assay samples
that included glucose as the predete;mined analyte and
ascorbic acid as the interferent. The test strips then
were visually compared to determine the degree and
intensity of a color transition. The experimental
results are illustrated in TABLE IV.
MS-1654
2~7~
- 69 -
T~BLE IV
Metal ComPlexes and Cooxidants to
Eliminate Ascorbate Interferences
Exp. Metal
5 No Buffer _ Com~lex _ _ Cooxidant
,
1 MES4) -o- _0_
2 MES -O- ~~
3 MES Ee(III)-~EDTA5) (5mM) -O-
4 MES -O- Bromate (20mM)
MES ~e(III)-HEDTA ~5mM) Bromate (20mM)
6 MES Fe~III)-HEDTA (5mM) Bromate (20mM)
7 MES ~~
8 MES Fe(III)-HEDTA ~5mM) Bromate ~20mM)
9 MES HAC6) (5mM) Bromate (20mM)
MES CPD7) (5mM) Bromate (20mM)
11 MES Pb(Ac)48) (Z5~M) Bromate (25mM)
12 MES Hg+~ 9) (25mM) Bromate (25mM)
13 MES Hg+2 (25mM) and -O-
Fe(III)-HEDTA (SmM)
14 MES ~9 (25mM) -O-
citratel) Fe~III)-HEDTA (5mM~ Chlorate (lOmM)
16 citrate Fe(III)-HEDTA (SmM) Chlorate (20mM)
17 citrate Fe(III)-HEDTA (5mM) Chlorate (30mM)
18 citrate -O- Chlorate (30mM)
19 citrate Fe(III)-HEDT~ ~5mM) Perchlorate (lOmM)
20 citrate Fe(III)-HEDTA (5mM) Perchlorate (20mM)
21 citrate Fe(III)-HEDTA (5mM) Perchlorate (30mM~
22 citrate -O- Perchlorate (30m~)
23 citrate Fe~III)-HEDTA (SmM) Iodate ~lOmM)
24 citrate Fe~III)-HEDTA ~5mM) Iodate (20mM)
25 citrate Fe(III)-HEDTA (5mM) Iodate (30mM)
26 citrate -O- Iodate (lOmM)
27 po411) Gan-His-Cul2) Bromate (5mM)
28 P04 Gan-His-Cu -O-
29 P04 Fe(II})-HEDTA (5mM) Chromate (SmM)
30 P04 -O- Chromate (5mM)
31 P04 E'e(III)-HEDTA (5mM) D8DH13) (5mM)
32 P04 -O- DBDH (SmM)
MS-1654
20678~6
-- 70 --
T~BLE IV - Continued
Exp. Glucosel)Ascorbate2) Strip
. . ..
100 100
2 100 50
3 100 100
4 100 100
-0-- 100
6 100 -0-
10 7 lG0 -0-
8 100 100
9 10~ 100
100 50
11 100 50
1512 100 50
13 100 50
14 100 50
100 100
1~ 100 100
2017 100 100
18 100 lûO
19 100 100
2~ 100 100
21 100 100
2522 100 100
23 . 100 100
24 100 100
100 100
26 100 100
30 27 100 100
28 100 100
29 100 100
100 100
31 100 100
35 32 100 100
MS-1654
~ . .
- :.
.
2067~
1) Glucose concentration in the test sample, in
mg/dL;
2) Ascorbate concentration in the test sample, in
mg/dL;
3) +~++ means reactivity of the test strip is
essentially equal to the reactivity observed when
the strip is dipped into control sample containing
no ascorbic acid,
++~ means slightly less reactivity than ~+,
++ means less activity than ~
+ means less activity than ++, and
- means no activity;
4) MES is 2-(N-morpholino)ethanesulfonic acid,
present at 200 mM to provide a pH of 6.5;
5) Solution of ferric ion complex with HEDTA;
6) HAC is hexamminecobalt(III) chloride;
7) CPD is cobalt~ 2,4-pentanedionate;
8) Pb(AC)4 is lead tetraacetate;
g) Hg+2 is a mercuric nitrate solution;
10) citrate is citrate buffer, present at 400 mM to
provide a pH of 6.5;
113 PO4 is phosphate buffer, present at 400 mM to
provide a p~ of 6.5;
12) Gan-His-Cu is a GANTREZ-histamine-copper complex
disclosed in U.S. Application Serial No. 337,620;
and
13) D~DH is dilsopropylbenzene dihydroperoxide.
TABLE IV shows the par~icular usefulness of
Fe~III)-~EDT~ as the metal complex and potassium bromate
as the cooxidant in an indicator reagent composition of
the present invention. Experiments 1 and 3 through 5
showed that the strip has no reactivity (no color
change) in the presence of 100 mg/dL ascorbate if either
one or both of the metal ion complex and the cooxidant
i5 absent from the indicator reagent composition.
MS-1654
2~6786~
- 72 ~
~owever, Experiment 2 showed that the strip demonstrates
a slight reactlvity in the absence of a metal ion
complex and a cooxidant when the ascorbate acid
concentration in the test sample was decreased to 50
mg/dL. Experiment 7 was a control experiment showing
the strip reactivity (maximum color change) towards
glucose in the absence of ascorbate, cooxidant and metal
ion complex. The color change demonstrated in
Experiment 7 was the standard. The color changes of the
test strips in the other experiments were compared to
the standard color change of Experiment 7. Experiment 6
demonstrated that the metal ion complex and cooxidant do
not adversely affec~ test strip reactivity when
ascorbate is absent from the test sample. Experiment 8
showed that the metal ion complex and the cooxidant
effectively overcame the interfering affects of ascorbic
acid, and provided a strip activity essentially
identical to the control Experiment 7.
Experiments 9 through 11 illustrated that
cobalt ion complexes and lead ion complexes are not
effective metal ion complexes in the indicator reagent
composition of the present invention. This result is
most easily demonstrated by comparing the reactivity of
the test strips of Experiments 9 and 10 to the
reactivities of the test strips of Experiments 8 and 2,
wherein the HAC/bromate-containing test strip (Exp. 9)
is unreactive, whereas the ~e(III3-HEDTA/bromate-
containing test strip (Experiment 8) is fully reactive,
and wherein the CPD/bromate-containing test strip
(Experiment 10) is less reactive than a test strip
absent a metal ion complex and a cooxidant (Experiment
2). Similarly, the lead ion complex and cooxidant
included in the test strip of Experiment 11 did not
increase the reactivity of the test strip over the
reactivity of the test strip in Experiment 2 that was
absent a metal ion complex and a cooxidant.
MS-1654
2~7~
- 73 -
Experiments 12 through 14 showed that mercuric
ion is an effective metal ion in the indicator reagent
composition of the present invention to eliminate
ascorbate interference. Experiment 14 illustrated that
mercuric ion alone provides a relatively highly-reactive
test strip in the presence of ascorbic acid. Including
Fe(III)-~E~TA in the test strip with the mercuric ion
tExperiment 13) did not increase the reactivity of the
test strip appreciably, but including bromate ion as a
cooxidant, with the mercuric ion, in the test strip
improved the reactivity of the test strip to provide a
maximum color transition tExperiment 12).
Experiments 15 through 18 demonstrated that
chlorate ion is an effective cooxidant in the indicator
reagent composition of the present invention.
Experiment 3 showed that including Fe(III)~HEDTA in a
test strip, without a cooxidant, provides a test strip
having no reactivity in the presence of 100 mM ascorbic
acid. Experiments 15 through 17 showed that test strips
including Fe(III)-HEDTA and chlorate ion demonstrate ~n
appreciably improved reactivity to test samples
including ascorbic acid in comparison to the test strip
of Experiment 3. Experiment 18 further showed that
chlorate ion i5 a cooxidant, as opposed to a primary
oxidant for ascorbic acid. In the absence of
Fe(III)-HEDTA, the tes~ strip of Experiment 18 exhibited
no reactivity in the presence of 100 mM ascorbic acid.
Therefore, the Fe(III)-~EDT~ is present to eliminate the
primary interference of the ascorbic acid, and the
chlorate ion is present to reduce the secondary
interfering afects of the ferrous ion.
Similarly, Experiments 19 through 22
demonstrated that perchlorate ion is an effective
cooxidant in the indicator reagent compo~ition of the
present invention. Like the above-discussed experiments
including chlorate ion, Experiments 19 through 21 showed
MS-1654
2~fi~6~
- 74 -
that test strips including Fe(III)-HEDTA and perchlorate
ion demonstrate a substantially improved reactivity to
test samples including ascorbic acid in comparison to
the test strip of Experiment 3. Experiment 22
illustrated that chlorate ion i5 a cooxidant, and not a
primary oxidant of ascorbic acidO The perchlorate ion
did not improve test strip reactivity in the absence of
Fe(III)-HEDTA, and therefore the perchlorate ion reduces
the secondary interfering affects of the oxidized form
of the metal ion in the metal ion complex.
In contrast to the chlorate ion and the
perchlorate, the iodate ion, as shown in Experiments 23
through 26, is a primary oxidant. Experiment 26 showed
that iodate ion, alone, eliminated the interf~ring
af~ects of ascorbate ion in a test sample, and therefore
provided a test strip having a maximum reactivity. The
presence of Fe(III~-HEDTA therefore is not necessary in
the case where iodate ion is present.
Experiments 27 and 28 showed that bromate ion
also is an effective cooxidant in an indicator reagent
composition including a cupric ion complex. The
particular cupric ion complex ~ested was disclosed in
the previously-discussed U.S. Patent Application Serial
No. 337,620. However, it is envisioned that other
cupric ion complexes also can be included with a
cooxidant selected from the group consisting of bromate
ion, chlorate ion, perchlorate ion, chromate ion,
organic oxidants like a peroxide, a hydroperoxide or a
N-halo compound, and combinations th~reof in an
indicator reagent composition of the present invention.
Experiments 29 and 30 showed that c~romate ion
also is an effective cooxidant in an indicator reagent
composition including Fe(III)-HEDTA. Similarly,
Experiments 31 and 32 showed that an organic oxidant,
like the hydroperoxide DBDHI also is an effective
MS-1654
2~8~t~
- 75 -
cooxidant in an indicator reagent composition including
Fe(III)-HEDTA.
Consequently, and in accordance with an
important feature of the present invention, the
continuing and substantial problem of ascorbic acid
interference in dry phase test strip assays for a
predetermined analyte is essentially eliminated, and a
more sensitive assay, especially to low concentrations
of a predetermined analyte, is provided. The indicator
reagent composition of the present invention essentially
eliminates the primary interfering affects of ascorbic
acid by including a metal ion complex. The indicator
reagent composition also essentially eliminates the
secondary interfering affects attributed to the reduced
form of the metal ion in the metal ion complex by
including a cooxidant selected from the group consisting
of bromate ion, chlorate ion, perchlorate ion, chromate
ion, organic oxidants like a peroxide, a hydroperoxide
or a N-halo compound, and combinations thereof. The
essential elimination of the primary and second~ry
interfering affects of ascorbic acid is an unexpected
improvement in the art o dry phase test strip assays
for a predetermined analyte, such as the assay for
_ occult blood, cholesterol or glucose, and similar
analytes that are capable of either interacting with an
oxidase enzyme or exhibiting peroxidase activity.
Consequently, and in accordance with an
important feature of the present invention, more
accurate and reliable assays for a predetermined analyte
in urine, blood serum, blood plasma and other test
samples can be performed by utilizing the indicator
reagent composition of the present invention. In
general, an indicator reagent composition of the present
invention, including a metal ion complex and a cooxidant
selected from the group consisting of bromate ion,
chlorate ion, perchlorate ion, chromate ion, an organic
MS-1654
206786~
- 76 -
oxidant like a peroxide, a hydroperoxide or a N-halo
compound, and combinations thereof, demonstrates an
improved ability to eliminate the primary interfering
affects of ascorbic acid and the secondary interfering
affects of the reduced form of the metal ion of the
metal ion complex; undergoes a more spectacular color
transition in response to the concentration of a
predetermined analyte in a test sample; does not
interfere with indicator dye oxidation by a
predetermined analyte and the redox mediator; and does
not interfere with ascorbate resistance provided by a
metal ion complex.
Obviously, many modifications and variations
of the present invention as hereinbefore set forth can
be made without departing from the spirit and scope
thereof and therefore only such limitations should be
imposed as are indicated by the appended claims.
MS~1654
